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Abstract 
Non-viral delivery vectors have potential advantages over the viral systems that currently are used 
extensively for delivering therapeutic genes of interest. However, non-viral gene therapy has low effi-
ciencies in vivo, in part due to the aggregation of the particles in the delivery system associated with 
serum proteins and other components of the blood. An effective technique for overcoming this prob-
lem to use PluronicTM block copolymers to cover the surfaces of the particles in the delivery system 
with polyethylene oxide, which decreases their charge density and reduces their interactions with the 
serum proteins. 
The objectives of this project were to characterize a Pluronic-gemini surfactant system to be 
used as non-viral vectors for gene therapy. Five Pluronics (L44, F68, F87, F108, and F127) were 
evaluated by studying their physiochemical properties, including particle size and zeta potential. Also, 
these systems were evaluated in OVCAR-3 cell culture for gene expression and cell viability. 
The in vitro systems showed small particle sizes (approximately 200 nm) for all Pluronics. 
The particle sizes in the systems were increased dramatically (up to 2000 nm) by adding di-
oleylphosphatidylethanolamine (DOPE) to the systems. The zeta potential of these systems shifted the 
negative zeta potential of DNA (-43 mV) to a positive value (+35 mV). The addition of DOPE had 
very little effect on zeta potential. 
The in vitro transfection efficiency in OVCAR-3 showed that all of the Pluronics were able to 
transfect OVCAR-3 at various DNA/gemini surfactant ratios. The highest transfection efficiency was 
obtained with Pluronics L44, F87 and F108. PluronicF127 demonstrated the lowest transfection effi-
ciency among the five Pluronics. Adding DOPE did not improve the transfection efficiency in any of 
the pluronic-gemini surfactant systems. 
The viabilities of the cells in these systems were high, and there were greater than the positive 
control (Lipofectamine 2000). The greatest cell viability (about 60%) was observed when the DNA to 
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gemini surfactant ratio was 1:2. After adding DOPE, the cell viability decreased in all of the Pluronics 
except for Pluronic F68. 
The results of this investigation indicated that Pluronic block copolymers can transfect 
OVCAR-3 cell cultures in vitro and that they had a low level of cytotoxicity. 
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Chapter 1 
Introduction 
1.1 Current Gene Therapy 
Gene therapy (GT) is a technique that is used to correct defective genes responsible for disease 
development. GT is also a novel and promising approach for the treatment of various diseases 
with the ultimate goal of developing vectors that are capable of efficient and safe delivery of 
transgenes to the tissue(s) of interest. Gendicine  (Shenzhen SiBiono Gen Tech), a gene therapeu-
tic for the treatment of head and neck cell squamous carcinoma (HNSCC) was approved for use 
in humans in China in 2003, and highlights the enormous potential effectiveness of gene therapy 
1. In September of 2005, the Food and Drug Administration of China approved another drug 
based on gene therapy for the treatment of cancerous tumor in the lungs and other organs, En-
dostar 2. Even though gene therapy offers promising treatment modalities, the difficulty of find-
ing safe and effective ways to transfer genes into the nucleus has not allowed gene therapy to 
evolve fully as a new treatment or for disease prevention 3. Gene therapy (GT) depends on using 
one of two kinds of vectors (viral or non-viral) to deliver genes into a patient’s host cells for ex-
pression and enable production of proteins to correct or moderate a specific disease.   
Pluronic block copolymers (non-viral vectors) have attracted considerable attention for 
gene deliver 4. The current research project investigated these copolymers extensively and 
showed their transfection efficiency as well as their cytotoxicity in vitro.   
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1.2 Viral Vectors in Gene Therapy  
Viral delivery, also known as transduction, involves the packaging of DNA (or in some cases 
RNA) into a virus particle. Gene transfer occurs by the normal viral infection route and is both 
efficient and cell selective. For this reason, viral delivery is the preferred strategy for in vivo gene 
therapy 5. About 67% of approved protocols use viral vectors, having developed a considerable 
number of different viral systems 6. The most common types of viral vectors that have been used 
in gene therapy include adenoviral (Ad), retroviral/lentiviral, or adeno associated viral (AAV). 
The adenovirus (Ad) is a non-enveloped virus with a 36-kilobase (Kb) double-strand DNA ge-
nome. Ad has several features that make it an attractive candidate as gene delivery vehicle, in-
cluding its ability to grow as high-titer recombinant virus, large transgene capacity, and efficient 
transduction of both dividing and non-dividing cells 7,8. To date, there are more than 51 human 
and nonhuman serotypes of Ad have been found to mediate gene delivery to a wide range of tis-
sues, such as respiratory tract, eye, and liver, and urinary tract 9.  
Retroviruses are positive sense RNA viruses, containing a single-chain 7-12 kb RNA ge-
nome which is converted to DNA by means of a reverse transcriptase encoded by the virus. The 
resultant viral-DNA is able to integrate in the host's cell genome 5. Genome integration, which 
permits stable and prolonged expression of delivered therapeutic genes, makes retroviruses attrac-
tive platforms as gene delivery vehicles 10. However, random insertion of these genes may result 
in carcinogenesis. In 2002, a young boy developed a leukemia-like condition after being treated 
with gene therapy using retroviral vector that resulted in gene insertion in an oncogenic site of the 
genome 11. In addition, vectors based on Human Immunodeficiency Virus-1 (HIV-1) and other 
retroviruses, pseudotyped with various envelope proteins, have been used to mediate gene deliv-
ery to both dividing and nondividing cells 12.  
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Another significant viral vector that has been used in clinical trials for gene therapy is 
adeno- associated virus (AAV). AAV is a nonpathogenic, nonenveloped virus with a 4.7 kb sin-
gle-stranded DNA genome which requires the presence of certain proteins from a helper virus, 
usually a member of the adenovirus or herpesvirus family, to complete its lifecycle 13. To date, 
more than 100 different serotypes of AAV have been isolated from both human and nonhuman 
tissues 14,15. Most studies have focused on AAV serotype 2 (AAV2), but recently several other 
serotypes, whose sequence variation in the viral capsid confers a broad range of gene delivery 
properties and options, have shown promising results 12.  
The main disadvantage of viral vectors is that they are lacking in safety measures for pa-
tients due to potential immune responses, and have the potential of possible integration of the 
therapeutic gene into the patients’ chromosomes which may lead to oncogenesis. In some clinical 
trials, several patient deaths have been attributed to the use of viral vectors 16. In addition, viral 
vectors have limitations in the size of plasmid they can encapsulate, proportion procedures, and 
the duration of time which they can be stored 17,18.  
1.3 Non-Viral Vectors in Gene Therapy  
Basically, in order to realize the astonishing potential of gene therapy in the treatment of 
diseases, non-viral vectors should be used as an alternative method. Non-viral vectors are based 
on cationic lipids or polymers. They are safe, cheap, and easy to produce in large scale, able to 
deliver large pieces of DNA that would not fit into the capsid of viral vectors, and are non-
toxic/non-immunogenic in most cases 19. Non-viral transfection vectors consist of cationic lipids 
or cationic polymers (polycations) which ,through electrostatic interactions, form polyelectrolyte 
complexes known as “lipoplexes” or “polyplexes”, respectively that neutralize and compact the 
DNA, provide protection from degradation, and enhance transport of the DNA into cell to in-
crease transgene expression 17,4,20. 
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1.4 Gene Delivery and Transfection 
The mechanism of formation of non-viral systems, their binding to DNA, and their entry into the 
cell have been studied extensively. Gene transfer in eukaryotic cells is a multi-step process in-
cluding the condensation of DNA, cellular uptake, release from the endosome, nuclear transport 
and vector unpacking and translation 20. DNA condensation is a reversible transition favored by 
the association of the cationic component (s) of the delivery system around the DNA phosphate 
groups resulting in the formation of polyplexes (cationic polymers) or lipoplexes (cationic lipids) 
21. The excess positive charges of the non-viral vectors interact electrostatically with the negative-
ly charged proteoglycans of the cell membrane 22. This is followed by non-specific endocytosis, 
phagocytosis or receptor mediated endocytosis which can be exploited to achieve greater specific-
ity. It is believed that the main entry route of the non-viral vectors to mammalian cells is endocy-
tosis; therefore, any structure facilitating membrane fusion, and allowing DNA release from lipo-
plexes and escape from endosomes could demonstrate high transfection efficiency 21.  
      The mechanism of action of gene transfer of lipoplexes has also been studied extensively. 
Early work suggested that lipoplexes were delivered into the cytoplasm by direct plasma mem-
brane fusion 23, but it is agreed now the lipoplexes are delivered through endocytosis 24, 25.  Fol-
lowing cellular uptake, lipoplexes destabilize the endosomal membrane, resulting in a flip-flop 
reorganization of phospholipids, which then diffuse into the lipoplex and interact with the cation-
ic lipids causing the DNA to dissociate into the cytoplasm 26.  
In contrast, polyplexes do not directly destabilize the endosomal membrane. It is believed 
that the mechanism of DNA escape from endosomes is associated with the ability of cationic pol-
ymers to protonate under the influence of the acidic pH inside the endosome creating a charge 
gradient resulting in water influx, endosomal swelling, and rupture of the endosome/lysosomes 
and release of the polyplexes 21. 
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After their release from the endosomes into the cytosol, the polyplexes must enter the nu-
cleus to undergo transcription. According to Moret et al., although the mechanism of transport of 
complexes through cytoplasm to nucleus is not completely understood, there is evidence that pol-
ycations protect DNA from cytosol nucleases and thus give higher probability for nuclear entry 27. 
The transfection efficiency of polyplexes critically depends on the cell cycle and is enhanced by 
mitotic activity 28. The best phases of the mitotic cell cycle for transfection are S, (for synthesis, 
when the DNA replication occurs) or G2, (the “growth” stage following DNA synthesis when 
protein synthesis occurs) when transfection is facilitated by natural nuclear membrane breakdown 
21. This can be exploited in certain cases such as the treatment of tumors by targeting the dividing 
tumor cells, while sparing the non-cycling normal cells 21. By contrast, lipoplexes were never ob-
served in the nucleus indicating that DNA enters probably as free DNA 29. Disassembly of the 
polyplexes and lipoplexes to allow the transcription apparatus of the cell to access the DNA effi-
ciently is the final stage in gene expression. Vector unpacking may be a limiting barrier to recep-
tor mediated gene delivery 30. According to Thomas and Klibanov, significant gene expression 
has been observed when polyplexes were injected directly into the nucleus suggesting that the 
dissociation of the complex can actually occur there, possibly mediated by DNA polymerase dur-
ing transcription in a manner analogous to the stripping of DNA from histone proteins 21. Release 
of the DNA from the DNA/liposome complex probably occurs at or before endosomal escape 
because passage through the nuclear membrane involves only uncomplexed DNA31. Passage 
through the nuclear membrane has to compete with the rapid degradation of uncomplexed DNA 
by cytoplasmic nucleases 31. As a result, the vector design has significant effects on the formation 
of lipoplex, its passage through the cell membrane, and the release of the lipoplex from the endo-
some and its subsequent dissociation 31. 
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1.4.1 Cationic Liposomes 
Cationic liposomes (CLs or lipoplexes) are considered one of the most efficient non-viral vectors. 
The cationic liposomes consist of positively charged lipid bilayers that have ability to complex 
with negatively charged naked DNA through electrostatic interaction resulting in complexes 
called lipoplexes 32. In 1987, Felgner described the first application of cationic liposomes to gene 
therapy 33. One of the recent applications of lipoplexed delivery was the growth of intratracheally 
inoculated H-358 human non-small-cell lung carcinoma tumors in nude mice was completely in-
hibited using an aerosol system administered by intratracheal instillation to deliver wild-type tu-
mor suppressor gene p53 lipoplexes to precancerous and cancerous endobronchial ells 34. Cationic 
liposomes have been examined for safety studies through different routes of administration such 
as intratumoral, intrapulmonary, intracerebral and intravenous with little or no toxicity reported in 
any of these studies 35. Liposomes have also other advantages such as simplicity of preparation, 
ability to produce in large amounts, ability to transfect non-dividing cells, and their versatility for 
use with any size or type of DNA/RNA 36.  
Most lipoplex formulations contain “helper” lipids, such as dioleoylphosphatidyl- ethano-
lamine (DOPE), or cholesterol (Chol), which provides added stability to the lipoplexes 32. The 
helper lipid is generally thought to also improve transfection efficiencies by assisting with escape 
of the DNA from the endosome after cellular uptake. Combination of cationic lipids and DNA in 
a micellar or liposomal form leads, generally, to a lamellar organization with DNA molecules 
sandwiched lipid bilayers. Some systems, for example those that contain the neutral lipid DOPE 
result in the formation of an inverted hexagonal structure 37 containing DNA in the center of the 
inverted hexagonal bilayers. According to Zhou and Huang, under physiological conditions, 
DOPE is a hexagonal phase-forming lipid, which is thought to contribute to its ability to increase  
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the transfection efficiency of DNA-liposome complexes by destabilizing the lamellar 
structure of the endsomal membrane lipids 25. 
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O
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C
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Figure  1.1 Chemical structure of DOPE 
 
Lipoplexes have some drawbackswhich include low transfection efficiency and lack of target 
specificity 38. Also, the formation of the lipoplex complex involves interaction among lipid mole-
cules, in addition to that with DNA itself. A major driving force for the complex formation is the 
release of low-molecular weight counter-ions that makes a large entropic contribution to the free 
energy of binding 39. The lipids’ hydrophobic segments are determinant in the macroscopic char-
acteristics of the ensuing liposomes, particularly their size, shape, and stability in the dispersed 
state, as well as interactions with other lipids, cell membranes, and DNA. This, in turn, affects the 
transfection efficiency of the resulting lipoplexes. Furthermore, liposomal formulations often re-
quire an adjuvant, such as DOPE for efficient delivery 40. 
1.4.2 Stealth Liposomes 
Stealth liposomes are poly-ethylene glycol (PEG)-coated liposomes, and they have been shown to 
be important for liposomal drug delivery 41. PEG is a linear polyether diol having several useful 
properties, such as biocompatibility, solubility in aqueous and organic media42, lack of toxicity, 
very low immunogenicity 43, and good excretion kinetics 44. The molecular weight and structure 
of PEG can be easily modulated for specific purposes, and it is easier and cheaper to conjugate 
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the polymer with the lipid. It has been demonstrated that grafting of PEG onto liposomes has 
many biological and technological advantages. According to Maria et al., the most important 
properties of PEGylated vesicles are their strongly reduced mononuclear phagocytic system 
(MPS) uptake and their prolonged blood circulation; consequently, they improve distribution in 
perfused tissues 41. In addition, PEG chains on the liposome surface prevent aggregation both 
with other vesicles and with serum proteins, and thus improve the stability of formulations. 
PEGylated liposomal doxorubicin (PLD) was the first and still the only stealth liposome formula-
tion to be approved in the USA and Europe for treatment of Kaposi’s sarcoma45, and recurrent 
ovarian cancer 46.   
1.4.3 Polyplexes 
In contrast to lipoplexes where the lipids must assemble into vesicle or bilayer structures, poly-
plexes do not require interaction of the polycation molecules with each other. As a result, poly-
plexes have greater control of macroscopic properties, and they are quite efficient without adju-
vants 21. In addition, polyplexes are composed of certain repeating structural units which are easi-
ly to manipulate by chemical modifications to achieve higher efficiency or cell targeting without 
the loss of activity 21. In other words, polyplexes can be synthesized in different lengths, with dif-
ferent geometry, and with substitution or addition of functional groups with relative ease and 
flexibility 32. Moreover, polyplexes do not contain a hydrophibic moiety and are completely solu-
ble in water 32. Basically, polyplexes are comprised of charged complexes of plasmid DNA and a 
cationic polymer, such as poly-L-lysine (PLL), polyethylenimine (PEI), polyamidoamine (PA-
MAM); starburst) dendrimers, or chitosan with a net positive charge 28. There are several poly-
plexes that have superior transfection efficiency and serum sensitivity in comparison to lipoplexes 
47. For example, Gebhart and Kabanov (2001) demonstrated using a COS-7 cell model transfected 
for 2 and 4 h at various DNA doses,  that linear Polyethyleneimine  (ExGenE 500) showed high 
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transfection in comparison with lipid transfection reagent (LipofectAMINE) 48. As a result, poly-
plexes have a promise to be a compelling part for non-viral gene therapy vectors.   
The choice of polycation is partly depends on the amphiphlic character or hydrophobic-
hydrophilic balance (HLB) of the polycation which affects the endocytosis of the resulting poly-
plexes and also the transfection efficiency. According to Thomas and Klibanov, attachment of 
hydrophobic substitutes that can interact with the lipids of the cell membrane could enhance en-
docytosis of the polyplexes and therefore transfection efficiency 21. 
           In order to obtain efficient transfection, the correct balance between gaining adequate 
access of the complexes to the cytoplasm without causing lethal damage to the cell must be 
achieved. Increasing toxicity has been observed with increasing molecular mass of the lipoplex 21. 
This toxicity can be reduced using lower molecular weight polycations with chemical modifica-
tion to improve transfection efficiency 49. 
Cationic lipid and polycations are usually ineffective when they are injected locally into a 
tissue; therefore, they display low levels of transgene expression in comparison with naked DNA 
20. However, polyplexes formed by biodegradable polymers, are thought to sustain release of 
DNA at the site of injection as the polycation is hydrolyzed 50,51. As a result, it is noteworthy to 
use different group of molecules that display the ability to increase transgene expression upon 
local administration of DNA in tissues. Non-ionic water-soluble polymers, such as Pluronic block 
copolymers, represent attractive alternative to the current non-viral gene delivery vectors because 
of their ability to prevent aggregation of delivery systems, increase transgene expression in a way 
that does not fit the current non-viral systems as well as they do not condense or bind DNA, 
which may affect the transfection efficiencies. Therefore, adding gemini surfactant will help in 
condensing DNA, and thus will improve the transfection efficiency. 
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1.5 Pluronic Block Copolymers in Gene Therapy 
1.5.1 Introduction 
PluronicTM block copolymers are nonionic polymers comprised of two blocks of polyethylene 
oxide (PEO) separated by a central block of polypropylene oxide (PPO) arranged in A-B-A tri-
block structure as illustrated in Figure 1.2 4. This arrangement results in an amphiphilic copoly-
mer in which the hydrophobic PO and hydrophilic EO segments can be modified to vary the size, 
hydrophobicity and lipophilicity of the pluronic. Copolymers with hydrophilic EO and lipophilic 
PO values are characterized by different hydrophilic–lipophilic balance (HLB), which plays im-
portant role in determining the effectiveness of Pluronics 4. Average diameter of the Pluronics 
ranges from about 20-80 nm.  The aggregation number (number of block copolymer unimers 
forming one micelle) generally ranges from several to over a hundred.  PluronicTM block copoly-
mers are synthesized by sequential polymerization of PO and EO monomers in the presence of an 
alkaline catalyst, such as sodium or potassium hydroxide 52. 
OH CH2CH2O CH2CHO CH2CH2O H
CH3
Polyethylene Oxide(PEO)
Polypropylene Oxide(PPO)
hydrophilic hydrophilic
hydrophobic
 
Figure  1.2 Pluronic Block Copolymers Chemical Structure 
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The most common feature of block copolymers is their ability to form micelles that are character-
ized by low critical micellar concentrations (CMC). The importance of the CMC can be summa-
rized in two points. First, the CMC determines the stability of micelles against possible dilution 
of the drug delivery system 53,54. Second, the CMC specifies the maximal achievable concentra-
tion of pluronic unimers to the targeted cells 55. Block copolymers form micelles with high effi-
ciencies due to the high degree of co-operative interactions within single polymer chains during 
the self-assembly process 56. These polymers are known to assemble into nanometer-scale aggre-
gates with a hydrophobic PO core, and a hydrophilic EO shell or corona 4. It has already been 
demonstrated that the steric stabilization effect of copolymer micelles reduces unwanted interac-
tions between cells and/ or proteins with the solubilized compounds and increases its circulation 
time 4,20. Due to the presence of hydrophobic PO core, the Pluronic unimers can adsorb on surfac-
es, interact with the hydrophobic and biological membrane, and even translocate inside the cells 
57. The EO corona can also be exploited for drug and gene delivery by incorporating compounds 
or ligands that are able to bind tissue-specific receptors and to achieve “targeting” of the desired 
tissue for gene therapy in vivo. In addition, polymeric micelles can be used as efficient carriers for 
compounds that alone exhibit poor solubility and low stability in physiological environment 4. 
Polymeric structures often tend to precipitate in water due to a localized hydrophobicity 
caused by the drug and the hydrophobic portion of polymeric chain. However, with a core/shell 
structure, the polymer may remain in water-soluble if the number of monomers in the shell-
forming block is more than core-forming block 58. The structure of the block copolymers has pro-
found impacts on the micellization process. The formation of the micelles become more favorable 
when the length of hydrophobic PO blocks increase resulting in lower values of critical micelle 
concentration (CMC) and critical micelle temperature (CMT) 59. On the contrary, an increase in 
the length of hydrophilic EO block decreases the stability of the micelles. Pluronic block copoly-
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mers are generally recognized to be safe for human use, particularly those with high content of 
PEO 60. Also, they have molecular weight less than 50,000 g mol-1 and can undergo renal clear-
ance; consequently, the toxicity will be reduced 61. 
1.5.2 Pluronic Block Copolymers for Gene Delivery 
Pluronics have been shown to increase the transfection of nucleic acids with viral and non-viral 
vectors particularly in combination with polycations at concentrations 500 times lower than estab-
lished toxicity levels 62. Scientific literature describes several examples of polyether-
polyethyleneimine copolymers as gene transfer agents. These are cationic copolymers linked to 
nonionic polymers obtained by grafting the PEI with nonionic polyethers such as polyethylene 
oxide (PEO) or pluronic copolymers. 
The research of Sriadibhatla et al. has demonstrated that pluronic block copolymers en-
hance expression of naked plasmid DNA in muscle, skin, tumor and other tissues, increase ex-
pression of genes delivered using polycation-DNA complexes both in vitro and in vivo, and in-
crease the transfection of cells with adenovirus or lentivirus vectors. Sriadibhatla’s studies indi-
cate that copolymers of intermediate hydrophobicity (HLB 9-16) with relatively large hydropho-
bic blocks (30-69 PO units) were the most effective. The authors compared in vitro and in vivo 
gene expression enhancement and found similarities in the magnitude of effects and pattern of 
activity of different Pluronics 63.  
Astafieva et al. compared a synthetic polycation (poly N-ethyl-4-vinylpyridinium bro-
mide) (PEVP) complexed with a plasmid DNA and later the same combination also mixed with 
1% Pluronic P85 for DNA intracellular uptake and transgene expression. The role of P85 was to 
intensify endocytic uptake of the complex into eukaryotic cells, and was to enhance the liberation 
of macromolecules from the endocytic compartments in the cytoplasm by enhancing internaliza-
tion and transfection of the DNA-PEVP complex into cells. Both the DNA uptake in the cells as 
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well as the transgene expression was significantly increased. The authors hypothesized that DNA 
condensation and recharging due to cationic chains on the surface of the complex, provide for 
increased binding of the complex to the plasma membrane, facilitating its entrapment into endo-
cytotic vesicles 64. Yang and colleagues have also reported that P85 promotes transfection en-
hancement in a promoter-dependent manner, suggesting a signaling pathway activation-
dependent mechanism 65. In addition, co-administration of P85 with DNA in skeletal muscles 
greatly increased gene expression in the injection tissue site and distinct organs, particularly the 
draining lymph node and spleen 66. Most recently, GFP transfection was significantly enhanced 
when Optison was administered with P85 more than Optison alone-treated mice 67.   
In other studies, the receptor-mediated gene delivery to hepatic cell lines, HepG2 us-
ing complexes of a plasmid DNA with an asialo-oroso-mucoidpoly-lysine conjugate was in-
creased fourfold in the presence of Pluronic F127 (one of the BASF pluronics being used in this 
study) 
37
. The Pluronic F127 also increased transfection efficiency when the cervical cancer cell 
line, C-33A was transfected with the polycation/DNA complex 4. Lemieux et al. have determined 
that a formulation based on the mixture of the block copolymers, Pluronic L61 and Pluronic F127 
increases gene expression 5-20 fold of uncomplexed plasmid DNA in skeletal muscle in mice. 
The authors found that lower concentrations of SP1017 (which is the block copolymer comprised 
of both L61 and F127) and at least ten times less DNA were required to achieve a significant in-
crease in gene expression and related physiological response. The high levels of transgene ex-
pression observed with SP1017 were sustained for a few weeks as comparison with naked DNA 
which faded after several days 68.   
Pitard and colleagues have discovered that the formulation containing single pluronic co-
polymers with plasmid DNA also enhanced the gene transfer in the muscle. Particularly, Pluronic 
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L64 improved the level of transfection efficiency more than the naked DNA in the skeletal and 
cardiac muscle 69.  
Kabanov et al. have investigated the toxicological aspects of injecting both single and 
multiple doses of various block copolymers in muscle tissue by morphological examination of the 
muscle tissue and by monitoring creatine phosphokinase levels, and have concluded that the tox-
icity of the block copolymers was proportional to their lipophilicity; the more lipophilic the co-
polymer the more severe the lesions. Using intramuscular injection has obvious advantages over 
myoblast transplantation and intramuscular injection of recombinant viral vectors. The muscles 
serve as a depot of DNA and could potentially be useful in the treatment of myopathies such as 
Duchenne’s muscular dystrophy or to induce humoral and cell-mediated immune response 
against infectious diseases and cancers 4.    
The mechanism of action of gene expression of Pluronics is not completely understood 70. 
However, depending on the applications above, the authors have speculated some mechanism of 
actions for Pluronics. For example, Pluronics form a gel that may act as a local reservoir for ade-
novirus release when the concentration is high (15-20 %) 71. Also, when Pluronics interact with 
cellular membrane, they facilitate cellular uptake of polyplexes 64 and naked DNA 68. In addition, 
Pluronics enhance DNA distribution through the muscle 68, and they increase transport of DNA 
from the cytoplasm in the nucleus of the muscle cells 69. Generally, the mechanism of actions in 
which Pluronics enhance gene expression are different from those of cationic lipids or poly-
cations 13.   
According to Kabanov et al., Pluronic block copolymers are promising agents as nonviral 
vectors for gene therapy applications. Pluronic block copolymers can modify the biological re-
sponse during gene therapy which leads to enhancement of gene expression and therapeutic effect 
of transgene. Also, Pluronics block copolymers are able to form novel self-assembling gene de-
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livery vectors that have superior effect to current known systems. In addition, Pluronics block 
copolymers have shown some promise as formulation agents.  
1.6 Gemini Surfactants in Gene Therapy 
According to Menger and colleagues, gemini surfactants are molecules consisting of two head 
groups and two aliphatic chains linked by a spacer as shown in Figure 1.3 72. Gemini surfactants 
are synthesized easily at low cost which is an important advantage for industrial drug manufactur-
ing. Gemini surfactants exhibit numerous advantageous properties including low critical micelle 
concentrations (CMC) and high surface activities. A low value of CMC is very important when 
considering surfactants as transfection vectors.  A high CMC maintains a high monomer concen-
tration that may be necessary to prevent the aggregation of anionic DNA particles, while a low 
CMC may provide a measure of complex stability, particularly during the delivery process via 
micellar aggregation 73,74. Also, gemini surfactants, in general, show very low toxicity and have 
demonstrated DNA transfection efficiencies as high as 90% 31.    
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Figure  1.3  A) General Structure of gemini Surfactant; B) structure of the m-s-m gemini surfac-
tant 
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The effect of variations in both the length of alkyl tails and the size of nature of spacer 
group of gemini surfactants has been demonstrated in many studies. Variations in the length of 
alkyl tail affect the properties of surfactant solution almost at the same effect of traditional mon-
omeric surfactants 18. For example, an increase in the length of alkyl tail of gemini surfactant with 
a fixed spacer group increases the Kraft temperature and decreases the natural logarithm of the 
CMC linearly 18. Low CMC allows gemini surfactant to package or encapsulate DNA, and this is 
one of the governing factor for low toxicity in gene delivery 75. The variations of spacer group of 
gemini surfactants are more complex because they result from steric, electrostatic, and hydropho-
bic interactions that serve to give rise to a rather rich array of aggregate structure in solution 18. 
 The cationic m-s-m gemini surfactant series is the most commonly studied where m and s 
refer to the alkyl tail length and the number of carbon atoms in the polymethylene spacer respec-
tively. The first appearance of m-s-m type of gemini surfactant used for transfection, was in 2001 
in a study by Rosenzwing and colleagues, who determined that surfactants having C6 spacer and 
oleyl (cis-9-octadecene) tails resulted in the highest overall transfection and, in particular, that the 
addition of the neutral helper lipid DOPE (1,2-dioleyl-sn-glycer-ophosphatidlyethanolamine) di-
minished transfection efficiency 76. Helper lipids work as stabilizing agent for the DNA-gemini 
surfactant complexes with C10, C12, and C14 tails 77. Also, the helper lipids are generally 
thought to improve transfection efficiencies by assisting with escape of the DNA from the endo-
some after cellular uptake by endocytosis 31. Badea has determined that transfection efficiencies 
are greatest for spacer group of size s≤4 or s≥12. The short spacing, where s=2, 3 and 4 and their 
increased transfection efficiency can be explained in terms of optimizing interaction with DNA 
phosphate groups 78. Badea also reported that the transfection efficiencies with 16-3-16 (gemini 
surfactant used in this study) increased when the alkyl tail length increased either in the presence 
or absence of DOPE 78.  
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1.7 Pluronic Block Copolymers and Gemini Surfactants in Gene Therapy 
As neutral polymers, the Pluronics will not interact with DNA 79; therefore the systems used in 
this investigation still require the use of a cationic component to complex and condense the DNA. 
As a result, the incorporation of a gemini surfactant in the gene delivery nanoparticles should be 
used. The presence of the gemini surfactant provides the resulting nanoparticles with a positive 
charge, which is necessary for the nanoparticles to interact with the negatively charged cell mem-
brane. As mentioned above, the PluronicTM block copolymers are also known to translocate inside 
cells, possibly facilitate the endosomal escape of DNA during transfection, and may activate cell 
signaling pathways that aid in the nuclear localization of the DNA. Generally, the interactions 
between gemini surfactants and neutral triblock copolymer systems are more complex 79. More 
details studies are required to see the effective of the pluronics and their dependence on gemini 
surfactants. As a result, this project examined the replacement of the more extensively studied 
polycations with nonionic polymers, specifically nonionic block copolymers i.e. Pluronics, while 
achieving the positive charge afforded in the use of polycations by the use of gemini surfactants 
which possess a positively charged head group. The project focused on the study of physiochemi-
cal properties of gemini surfactants (16-3-16) in combination with Pluronics L44, F68, F87, F108 
and F127 as well as it examines the transfection efficiency and toxicity of these systems. The 
properties of the Pluronics used in this study are listed in Table 1-1.  
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Table  1-1 Physiochemical Characteristics of Pluronics Block Copolymers 20 
 
aThe average molecular weight provided by the manufacturer (BASF Co., Parsippany, NJ).                                            
bThe average numbers of EO and PO units were calculated using the average molecular weights.                                   
cHLB values of the copolymers the cloud points were determined by the manufacturer.                                                                
dCMC values were determined previously using Pyrene probe 80 
 
 
 
 
 
 
 
 
Copolymer MWa Average no. 
of EO 
units(Npo)b 
Average no. 
of PO 
units(Npo)b 
HLBc Cloud Point 
in 1% aque-
ous solution, 
Cc 
CMC, Md 
L44 2200 20.00 22.67 16 65 3.6×10-3 
F68 8400 152.73 28.97 29 ˃100 4.8×10-4 
F87 7700 122.50 39.83 24 ˃100 9.1×10-5 
F108 14600 265.45 50.34 27 ˃100 2.2×10-5 
F127 12600 200.45 65.17 22 ˃100 2.8×10-6 
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1.8 Rationale and the Hypothesis  
As a focus for this research, Pluronic block copolymers offer promise for developing non-viral 
vectors. Their small size and amphiphilic structure facilitate an effective approach as nanoparti-
cles for gene therapy applications.  For effective gene therapy, Pluronics must meet two require-
ments: the ability to efficiently facilitate gene delivery and exert minimal or no toxic effect on 
their biological host and its cells. As a result, the main goal of this project was to evaluate these 
Pluronics in combination with DNA and cationic gemini surfactant.  
This project will assess the following:  
1- Physiochemical properties such as zeta potential and the particle size of Pluronic-GS-DNA  
2- Transfection efficiency and cytotoxicity of these systems  
The hypothesis for this project is the following;  
Non-viral nanoparticles based on a combination of Pluronic block copolymer and gemini surfac-
tant can improve the efficiency of DNA transfection in vitro.  
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1.9 Objectives of the Research 
1.9.1 Primary Objective 
The primary objective of the project is to examine the transfection efficiency of five Pluronic 
block copolymers and test the ability they have for delivering plasmid DNA into a nucleus.  
1.9.2 Specific Objectives 
1- Purify and extract plasmid DNA to be used in a delivery system on OVCAR-3 cell line.  
2- Prepare gemini surfactant/Pluronic-based systems to be used in vitro delivery.  
3- Prepare gemini surfactant/Pluronic-based systems in addition with DOPE to be used in 
vitro delivery.  
4- Evaluate the physiochemical characterization of gemini surfactant/pluronics-based systems 
either used with DOPE or not by size and zeta-potential measurements. 
5- Optimize OVCAR-3 cell culture, transfection, sample collection and detection methods. 
6- Evaluate the relationship between the physicochemical properties of Pluronics delivery sys-
tems and their efficiency in vitro. 
7- Set-up and validate fluorescence activated cell sorting (FACS) and cell viability.  
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Chapter 2 
Materials and Methods 
2.1 Purify and extract plasmid DNA to be used in delivery system on OVCAR-3 cell line  
 
Plasmids were generated from 4 batches of 50 ml JM109 Escherichia coli cultures, harboring the 
pVGtelRL plasmid, after growing individual colonies in 50 ml of LB + Kan (50 μg/ml) with aera-
tion for approximately 16 hours. Cultures were harvested and plasmid extracted with E.Z.N.A. 
Plasmid Maxi-Prep Kit (Omega, VWR). Plasmid DNA (pDNA) concentration and purity was 
determined using a NanoDrop spectrophotometer (Thermo Scientific, USA). pDNA extraction 
was confirmed by gel electrophoresis using a 0.8% agarose gel at 100V for 1 hr followed by gel 
imaging (AlphaImager, Alpha Innotech). 
2.2 Prepare gemini surfactant/pluronic-based systems to be used in vitro delivery 
The Pluronic-block copolymers (BASF) (L44, F68, F87, F108, and F127) were dissolved in 
phosphate buffered saline (PBS) at concentrations of 0.1 CMC, 1 CMC, and 2 CMC. Before 
preparation of the transfection complexes, each Pluronic solution was filtered using a 0.2 μm ster-
ile filter.  0.1, 1, and 2 cmc of Pluronics were added/ well.   
Gemini surfactant 16-3-16 (synthesized in the lab) at a concentration of 1.5 mM, was dissolved in 
mili-Q water and sonicated for 30 minutes until completely dissolved. Before preparation of the 
transfection complexes, a gemini surfactant solution was filtered using a 0.2 µm sterile filter, and 
0.4 μL of gemini surfactant was added/ well.  
The plasmid–gemini complexes (PG) were prepared as follows: 0.4 μg plasmid was mixed with 
an aliquot of gemini surfactant solution added to obtain a 2, 5, or 10 +/- charge ratio and incubat-
ed at room temperature for 15 minutes prior to transfection. The plasmid–gemini–Pluronic sys-
tems were prepared by mixing the plasmid (0.4 μg/well) with the gemini surfactant solution (2, 5,  
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or 10 +/- charge ratio) and incubated at room temperature for 15 minutes. To this mixture, 0.1, 1, 
and 2 cmc of Pluronics were added. Cells were transfected after 30 minutes incubation at room 
temperature.   
2.3 Prepare gemini surfactant/pluronic-based systems in combination with DOPE to be 
used in vitro delivery 
Lipid vesicles were prepared using sonication techniques. 1, 2 dioleyl-sn-glycero- 
phosphatidylethanolamine (DOPE) (Avanti Polar Lipids, Inc.) and α-tocopherol (Sigma-Aldrich) 
in 5:1 weight ratios were dissolved in 100% ethanol (Commercial Alcohols Inc., Brampton, ON) 
in a round bottom flask. The solvent was evaporated using rotary evaporation at 100 rpm at 60
o
C, 
producing a thin film deposited on the walls of the flask. Traces of organic solvent from the lipid 
were removed with a high vacuum overnight. Glass beads were added to the flask, and the lipid 
was resuspended in 0.1, 1, and 2 cmc Pluronics (pH= 9). The suspensions were bath-sonicated 
(Branson 2200, Cleansonic, Orange, VA) for 3 hours at 55
o
C. The suspensions were then filtered 
using 0.45 μm Acrodisc
® 
filters.  
The plasmid-gemini complexes (PG) were prepared as follows: 0.4 μg plasmid was mixed with 
an aliquot of gemini surfactant solution added to obtain a 2, 5, or 10 +/-charge ratio and then in-
cubated at room temperature for 15 minutes prior to transfection. The plasmid-gemini-
Pluronic+DOPE systems were prepared by mixing the plasmid (0.4 μg/well) with the gemini sur-
factant solution (2, 5, or 10 +/- charge ratio) and incubated at room temperature for 15 minutes. 
Then, 15 μL of DOPE vesicles were added to this mixture. Cells were transfected after 30 minute 
incubation at room temperature. 
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2.4 Evaluate Physiochemical characterization by size and zeta-potential measurements 
2.4.1 Particle Size Analysis 
Particle size is the diameter of the sphere that diffuses at the same speed as the particle being 
measured. The Zetasizer system determines size by first measuring the Brownian motion of the 
particles in a sample using Dynamic Light Scattering (DLS) and then interprets a size by using 
established theories.  
       DLS measurements are performed by passing a laser light beam through a sample in 
aqueous solution. According to quantum field theory, light is emitted as photons that interact with 
matter; in this case particle size is evaluated using the first principles that govern the processes of 
diffusion, which depend on particle size and temperature and viscosity of the suspension solvent. 
The technique relies on the effect of time-dependent light scattering of the random motion of sus-
pended particles (Brownian motion) that depends on particle size. Brownian motion is the move-
ment of particles due to collision with the particles of the liquid that surrounds the particle matter 
in a water medium in a highly localized manner, but where the probability distributions of these 
interactions follow a wave-like behavior. The particles in a liquid move randomly and their speed 
of movement is used to determine the size of the particle 81.     
The instrument measures rapid time variations on a scale of microseconds of the scattered 
light intensity due to interference between light waves scattered by diffusing particles illuminated 
with a coherent light beam. When a dilute sample is illuminated with a collimated steady mono-
chromatic light source, beginning at t0,  the time-dependent irradiance of light scattered by mono-
disperse spherical particles at a given angle can be measured. The time-dependence of that irradi-
ance comes from the time-dependent interference of light waves scattered by each particle at that 
angle. The interference is time-dependent because, as the particles are pushed by the fluid mole-
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cules away from their positions at time t0, the conditions for the interference of waves that are 
scattered by these particles will change.   
Single scattering dominates, and particles can diffuse essentially independently of each 
other, with small particles diffusing faster than large ones. Close to t0, the instantaneous scattered 
light intensity is much the same as at t0. However, as the particles drift further apart, this correla-
tion decays until the scattered light intensity no longer correlates with the initial intensity. The 
rate at which the correlation between these fluctuations of the light intensity scatter and angle de-
cays with that time delay is thus a measure of the rate of diffusion of the particles and indirectly a 
measure of particle size.  
The translocation diffusion coefficient, once determined from the above process, can be 
related to the apparent hydrodynamic radius (Rh) using the Stokes’s – Einstein equation:    
D
kT
Rh
6
  
Where, k is the Boltzmann constant, T is the absolute temperature, η is the solvent viscosity, and 
D is the translational diffusion coefficient 82.  
The translational diffusion coefficient, as a function of particle size, depends not only on the size 
of the particle core, but also on its surface structure as well as the concentration and types of ions 
in the medium.  Ions can affect particle diffusion speed by changing the thickness of the electric 
layer (the Debye length). A high conductivity medium will suppress the electric double layer and 
the measured hydrodynamic diameter. Surface structure also affects the diffusion speed. For ex-
ample, a polymer layer projecting into the medium will slow diffusion speed more than if that 
polymer is lying flat on the particle surface.  
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Particles size measurements were performed using disposable Solvent Resistant Micro 
Cuvette (ZEN0040) in a Malvern Zetasizer NanoZS (Malvern Instruments, Worcestershire, UK), 
while particle size distributions were calculated using the Malvern DTS software.  
2.4.2 Zeta Potential Analysis 
Zeta potential (ζ) is the electrostatic potential that exists at the boundary between two layers of 
ions, namely, the compact layer and the diffuse layer, that surround a particle in solution. It is an 
important property for understanding colloidal and interfacial behavior. Zeta potential is meas-
ured using a combination of the measurement techniques, namely, Electrophoresis and Laser 
Doppler Velocimetry, sometimes called Laser Doppler Electrophoresis. This method measures 
how fast a particle moves in a liquid when an electrical field is applied – i.e., its velocity. The 
zeta potential of the sample will determine whether the particles within a liquid will tend to floc-
culate (stick together) or not 81. Zeta potential measurements were performed using Disposable 
capillary cell (DTS1070) using a Malvern Zetasizer NanoZS; zeta potential distributions were 
calculated using the Malvern DTS software.  
One of the most common techniques used in measuring zeta potential is electrophoresis. 
When an electric field is applied across an electrolyte, charged particles suspended in the electro-
lyte are attracted towards the electrode of the opposite charge. Viscous forces acting on the parti-
cles will tend to oppose this movement. When equilibrium is reached between these two opposing 
forces, the particles move with a constant velocity. This velocity will depend on several variables, 
including the strength of the electric field or voltage gradient, the dielectric constant of the medi-
um, the viscosity of the medium and the zeta potential. The velocity of a particle in a unit electric 
field is referred to as its electrophoretic mobility.  
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Zeta potential is related to the electrophoretic mobility using the Henry equation:- 
UE = 2 ε ζ f (κa) 
   3η 
where UE = electrophoretic mobility, ζ = zeta potential, ε = dielectric constant, η = viscosity and 
f (κa) = Henry’s function. 
The units of κ, termed the Debye length, are a reciprocal length and κ-1 is often taken as a meas-
ure of the “thickness” of the electrical double layer. The parameter ‘a’ refers to the radius of the 
particle and therefore κa measures the ratio of the particle radius to the electrical double layer 
thickness. Electrophoretic determinations of zeta potential are most commonly made in aqueous 
media and moderate electrolyte concentration 83.  
For particle size and zeta potential measurements, the transfection mixture with the pVG-
telRL-GFP plasmid (0.4 μg/mL final concentration in the formulation), gemini surfactants 
(charge ratios of 2, 5 or 10 +/-), Pluronics (0.1, 1, and 2 CMC), and Pluronics+DOPE vesicles 
were prepared as described earlier for the transfection of OVCAR-3. Samples were run in tripli-
cate, and represented as an average ± SD. 
2.5 Optimize OVCAR-3 cell culture, transfection, sample collection and detection methods 
 
OVCAR-3 cells (ATCC) were grown to 90% confluency in 75-cm2 tissue culture flasks in 
RPMI-1640 medium supplemented with 20% FBS (+FBS, -Ab). The RPMI (+FBS, -Ab) medium 
was changed to RPMI-1640 medium (without FBS), RPMI (-FBS, -Ab) one hour prior to trans-
fection. The cells were transfected with the following pVGtelRL plasmid using Lipofectamine 
tm2000 (Invitrogen Life Technologies). For each well, 0.4 μg plasmid was used. The transfection 
method followed the manufacturer’s protocol and was optimized for the OVCAR-3 cells. Briefly, 
0.4 μg plasmid was mixed with 0.4 μL lipofectamin tm2000 reagent in 100 uL MEM and incubat-
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ed at room temperature for 15 minutes. 0.4 μL of Lipofectamine reagent mixed with 50 μL of 
MEM was added to the plasmid. After incubating the mixture for 15 minutes at room tempera-
ture, it was added dropwise to cells covered with 200 μL of fresh MEM. The gemini surfactants 
were prepared at 1.5 mM and 0.8, 2, and 4 µL/well were added for the transfection, resulting in a 
2:1, 5:1, and 10:1 charge ratio of gemini surfactant to plasmid DNA. Gemini surfactant was 
mixed with plasmid DNA and incubated at room temperature for 15 minutes. The Pluronic solu-
tions were used at 0.1, 2, and 1 CMC, and the required amount of Pluronic (either with DOPE or 
not) was added, and incubated for 30 minutes. Then, the mixture was added dropwise to the wells 
that contained OVCAR-3. After five hours, the transfection mixture in each well was replaced 
with 500 µL of RPMI (+FBS, -Ab) medium, and the cells were incubated overnight in a tissue 
culture incubator at 37 °C and 5% CO2.   
2.6 Fluorescence activated cell sorting (FACS) and cell viability 
In the next day, 500 µL of RPMI (+FBS, -Ab) medium in each well was aspirated, and 200 uL of 
triple express (Life-Technology Inc.) was added to detach the cells. Then, 1000 uL of RPMI 
(+FBS, -Ab) medium was added. Afterwards, the cells were collected in 15 ml tubes and centri-
fuged at 0
o
C and 1000 ×g for 5 minutes. GFP expression cells were washed with phosphate buff-
ered saline (PBS) twice after centrifuging. Green fluorescent protein (GFP) expression was quan-
tified using a fluorescence activated cell sorting (FACS) technique. Then, 50,000 cells per sample 
were analyzed with the FACS instrument (guava easyCyte™ Flow Cytometer) for protein expres-
sion and propidium iodide (PI) was examined for cell viability. 
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Chapter 3 
Results and Discussion 
3.1 Evaluate Physiochemical characterization of gemini surfactant/pluronics-based nano-
particles and their ability to combine with DNA (Particle size and zeta potential)  
3.1.1 Particle Size Results 
Particle size and charge of the surface measurements of delivery systems are very significant fac-
tors in assuring that delivery systems are appropriate for gene delivery. Dynamic Light Scattering 
(DLS) was used to monitor the polyplexe particle size distributions.   
  Particle size of gene vector is an important factor that impacts the access and passage of 
the gene vector through the targeting site 84, and it also impacts the stability of colloidal particles 
in solution. For efficient endocytosis and gene transfer, particle size of the complex should be 
below (200 nm) and compact 85. The particle size depends on many factors, including DNA con-
centration, sequence of addition of cationic surfactant (gemini surfactant) or DNA to Pluronics 
during preparation. The particle sizes of polyplexes are closely related to the overall surface 
charge of the particles. According to Radwan 86, transfection of lipoplexes was directly related to 
the biophysical properties of lipoplexes. Radwan’s team found that lipoplexes of high or low (+/-) 
charge ratios were small in size, while lipoplexes of near-neutral charge ratios were large. 
In this project, the particle size of Pluronic-GS-DNA complex ranged from about 130 to 
1450 nm.  Tables 3.1- 3.5 and Figures 3.1-3.3 show the particle size data of Pluronics L44, F68, 
F87, F108, and F127 with three concentrations of Pluronics: below CMC, at CMC, and above 
CMC. Three ratios (1:2, 1:5, and 1:10) of DNA: gemini surfactant 16-3-16 was added. As shown 
by this data, the average particle size of Pluronic-GS was variable. It is clear that 0.1 CMC ob-
tained the largest size among all five Pluronics. However, when DNA was added, the average 
particle size of Pluronic-GS-DNA complex ranged from about 130 to 200 nm. Almost 80 % of 
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the complexes have particle sizes below 200 nm, except pluronic L44 at ratio 1: 2 at all concen-
trations (0.1 CMC, 1 CMC, and 2 CMC). This has an overly large particle size that reached ap-
proximately 1450 nm. Moreover, Pluronic F127 had a slightly larger particle size at around 250 
nm. These results indicate that GS and Pluronics undergo strong compaction and condensation 
with DNA molecules.  
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Table  3-1 Particle Size and Zeta Potential of Pluronic L44+GS and L44+GS+DNA 
     GS=Gemini Surfactant 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 L44+GS   L44+GS+DNA       L44+GS L44+GS+DNA 
     
0.1 CMC L44(1:2) 217±28 1458±205 35±29 -25±14 
1 CMC L44(1:2) 3.6±0.03 955.5±133 21±2 -21.5±1 
2 CMC L44(1:2) 3.8±0.2 1022±24 -1.4±6 -5.7±2.2 
     
0.1 CMC L44 (1:5) 44±14 130.5±0.9 34.1±20 37±1.3 
1 CMC L44 (1:5) 7.5±0.2 173.6±1.7 18.5±3 23±0.8 
2 CMC L44 (1:5) 3.4±0.3 417±8.2 -0.6±3 18.5±1 
     
0.1CMC L44(1:10) 14±1.2 163.6±1.1 2.3±2 44±6.9 
1 CMC L44 (1:10) 6±0.04 192.6±13 8±9.3 26.5±0.2 
2 CMC L44 (1:10) 24.5±24 141±2 13±10 23±1.3 
 
 
Table  3-2 Particle Size and Zeta Potential of Pluronic F68+GS and F68+GS+DNA 
      GS=Gemini Surfactant 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F68+GS   F68+GS+DNA       F68+GS F68+GS+DNA 
     
0.1 CMC F68(1:2) 290±54 151±3 3.4±5.9 12±0.3 
1 CMC F68(1:2) 7.8±1.1 155±2.7 0.4±4.9 -3.11±4.7 
2 CMC F68(1:2) 7±0.6 108±7.8 5.8±3.6 -10.8±11.2 
     
0.1 CMC F68 (1:5) 120±8.8 131.7±1.5 26.5±15.7 28.60.9±1.3 
1 CMC F68 (1:5) 25±8.7 113±1.6 15.9±0.7 1.98±0.6 
2 CMC F68 (1:5) 7.1±0.06 104±7.5 9.3±1.9 1.71±2.34 
     
0.1CMC F68(1:10) 339.5±29.6 174±3.8 31.2±13.3 31±0.3 
1 CMC F68 (1:10) 125.7±26.4 116±0.6 21.6±1.42 8.7±1.41 
2 CMC F68(1:10) 88.6±2.3 88.6±2.3 8.7±4.6 2.39±0.98 
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Table  3-3 Particle Size and Zeta Potential of Pluronic F87+GS and F87+GS+DNA 
      GS= Gemini  Surfactant 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F87+GS   F87+GS+DNA       F87+GS F87+GS+DNA 
     
0.1 CMC F87(1:2) 446±61.6 177.7±8 16.2±9.24 6.40±2.89 
1 CMC F87(1:2) 122.8±67 267±15.8 2.07±0.7 -7.07±11.3 
2 CMC F87(1:2) 47.7±20 173.7±4.6 2.95±2.77 0.014±0.03 
     
0.1 CMC F87(1:5) 31.9±1.5 168.8±2.6 27.5±13.2 25.4±0.3 
1 CMC F87(1:5) 31.15±5 143.3±11.8 1.76±0.9 1.26±0.6 
2 CMC F87 (1:5) 17.8±0.6 129.5±7.9 0.39±0.98 0.25±0.7 
     
0.1CMC F87(1:10) 49.3±17 191.4±5.2 28.2±22.2 22.1±2.84 
1 CMC F87(1:10) 140±61 114.4±9.3 2.16.6±0.14 3.27±2.08 
2 CMC F87(1:10) 58.4±59.6 154.2±4 2.61±1.78 1.59±1.23 
 
 
Table  3-4 Particle Size and Zeta Potential of Pluronic F108+GS and F108+GS+DNA 
    GS=Gemini Surfactant 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F108+GS   F108+GS+DNA       F108+GS F108+GS+DNA 
     
0.1 CMC F108(1:2) 145±50 195.7±7 9.13±5.2 -1.18±9.6 
1 CMC F108(1:2) 62±18 156±1.94 0.4±0.9 -1.12±0.9 
2 CMC F108(1:2) 79±18 154.5±4.3 -0.7±1.7 -4.13±3 
     
0.1 CMC F108(1:5) 406.5±205 166.9±4 25±13.8 35.6±3.6 
1 CMC F108(1:5) 54.6±17.5 177±3.5 2.1±1.3 -0.62±0.2 
2 CMC F108 (1:5) 28.5±9 152±6.9 0.13±0.5 -0.8±0.4 
     
0.1CMCF108(1:10) 85±54.7 167±3.9 16.5±9.5 21.8±3 
1 CMC F108(1:10) 84±35 190±12.6 0.67±1.7 0.0035±0.6 
2 CMC F108(1:10) 22±5.7 176±6.7 0.01±0.7 -0.7±0.5 
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Table  3-5 Particle Size and Zeta Potential of Pluronic F127+GS and F127+GS+DNA 
    GS=Gemini Surfactant 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F127+GS   F127+GS+DNA       F127+GS F127+GS+DNA 
     
0.1 CMC F127(1:2) 93.7±4.5 267±5     -1.67±8 3±1.5 
1 CMC F127(1:2) 81±19 243±4      0.13±1 -1±0.7 
2 CMC F127(1:2) 80±20 212±4     -0.5±0.5 -1.6±2.3 
     
0.1 CMCF127 (1:5) 71±7 155±1.6      16±7 28±5 
1 CMC F127 (1:5) 28±1.4 280±21      0.8±0.5 1±0.9 
2 CMC F127 (1:5) 34.7±17 278±16     -0.2±1 -0.9±0.9 
     
0.1CMCF127(1:10) 112±8 187±5      5.8.±6 33±0.6 
1 CMC F127 (1:10) 46±2 293±25      0.4±0.5 10±1 
2 CMC F127 (1:10) 60±26 167±13     -0.4±1.6 -0.1±0.5 
 
Tables 3.6-3.10 and Figures 3.1-3.3 indicate the particle size of all five Pluronics after adding 
DOPE. The particle size of all five Pluronics increased dramatically. All Pluronics obtained a size 
more than 200 nm. Consequently, it is quite evident that there was weak or no complexation be-
tween DNA and Pluronic-GS-DOPE.  
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Figure  3.1 Particle size of the Pluronics at ratio 1: 2 A) Particle size of the Pluronics at 0.1, 1, and 
2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with DOPE. Re-
sults are shown as mean (n=3), errors bars represent standard deviation. 
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Figure  3.2 Particle size of the Pluronics at ratio 1: 5 A) Particle size of the Pluronics at 0.1, 1, and 
2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with DOPE. Re-
sults are shown as mean (n=3), errors bars represent standard deviation. 
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Figure  3.3 Particle Size of the Pluronics at ratio 1: 10 A) Particle size of the Pluronics at 0.1, 1, 
and 2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation. 
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3.1.2 Zeta Potential Results  
Zeta potential (ζ) is another important factor for the stability of colloidal delivery systems and 
DNA transfection. The stability of colloidal systems is determined by a combination of electro-
static and steric repulsion. The magnitude of the zeta potential gives an indication of the potential 
stability of the colloidal system. If all the particles in suspension have a large negative or positive 
zeta potential then they will tend to repel each other and there will be no tendency for the parti-
cles to come together. However, if the particles have low zeta potential values then there will be 
no force to prevent the particles from coming together and flocculating.  
The general dividing line between stable and unstable suspensions is generally taken at 
either +30 or -30 mV. Particles with zeta potentials more positive than +30 mV or more  
negative than -30 mV are normally considered stable 81. However, if the particles have a density 
different from the dispersant, they will eventually sedimentalize forming a closely packed bed 
(i.e. a hard cake). 
The results of Zeta Potential (ζ) of Pluronic-GS and Pluronic-GS-DNA complex are 
shown in Tables 3.1-3.5 and Figures 3.4-3.6. Zeta potential measurements indicated electrostatic 
interaction between Pluronic-GS and plasmid DNA, since the negative charge of plasmid DNA (-
43mV) shifted to positive values. It is clear from the data that the zeta potential average of Plu-
ronic-GS-DNA complex has a strong positive charge at 0.1 CMC. However, the surface charge at 
1 CMC and 2 CMC was neutral or has very weak positive charge. This decrease in surface charge 
likely resulted from the large amount of Pluronics (have neutral charge) that dilute with gemini 
surfactant and DNA and led to a decrease in the surface charge of Pluronic-GS-DNA complex.  
Adding DOPE to Pluronics maintains the negative charge of Pluronic-GS-DNA complex. 
Results of zeta potential after adding DOPE are shown in Tables 3.6-3.10 and Figures 3.4-3.6.  
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Table  3-6 Particle Size and Zeta Potential of Pluronic L44+D+GS and L44+D+GS+DNA 
GS=Gemini Surfactant, D=DOPE 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 L44+D+GS   L44+D+GS+DNA       L44+D+GS L44+D+GS+DNA 
     
0.1 CMC L44(1:2) 843.6±36.5 214±3 -5±6.5 -29±1.3 
1 CMC L44(1:2) 496.7±15 268±4.4 -11±5 -47±3 
2 CMC L44(1:2) 569±17 239±4.4 -12±7 -41±3 
     
0.1 CMC L44 (1:5) 942±55 1355±55 0.3±0.2 -16±14 
1 CMC L44 (1:5) 506±21 1393±17 -5.5±4 -19±12 
2 CMC L44 (1:5) 644±28 1256±85 -6±2 -10±5 
     
0.1CMC L44(1:10) 873±17 1396±24 13.5±6 0.5±7.6 
1 CMC L44 (1:10) 1168±67 1470±45 4±5 1.86±9.6 
2 CMC L44 (1:10) 668±22 1585±59 6.4±11 1±1.2 
 
 
Table  3-7 Particle Size and Zeta Potential of Pluronic F68+D+GS and F68+D+GS+DNA 
GS=Gemini Surfactant, D=DOPE 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F68+D+GS   F68+D+GS+DNA       F68+D+GS F68+D+GS+DNA 
     
0.1 CMC F68(1:2) 215±3 224±2 -10±7 -27±4 
1 CMC F68(1:2) 424±6 606±47 -0.03±0.007 -20±13 
2 CMC F68(1:2) 314±55 370±56 -5 ±2 -0.4±0.7 
     
0.1 CMC F68 (1:5) 192±5 1563±57 17±9 -17±15 
1 CMC F68 (1:5) 1252±72 936±35 -8±6 -49±8 
2 CMC F68 (1:5) 304±28 582±33 -1.8±3 -40±9 
     
0.1CMC F68(1:10) 271±1.7 292±6 22±12 -12±10 
1 CMC F68 (1:10) 1955±270 525±55 -0.7±7 -31±26 
2 CMC F68 (1:10) 1552±96 392±44 1.24±7 -16±17 
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Table  3-8 Particle Size and Zeta Potential of Pluronic F87+D+GS and F87+D+GS+DNA 
GS=Gemini Surfactant, D=DOPE 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F87+D+GS   F87+D+GS+DNA       F87+D+GS F87+D+GS+DNA 
     
0.1 CMC F87(1:2) 258±8 338±16 -17±4 -0.01±0.05 
1 CMC F87(1:2) 200±2.3 525±31 -22±2 -29±0.9 
2 CMC F87(1:2) 305±10 278±7.5 -15±1.4 -21±2.5 
     
0.1 CMC F87 (1:5) 463±21 338±28 -15.5±3 -41±5 
1 CMC F87 (1:5) 223±20 564±10 -22±1 -27±0.7 
2 CMC F87 (1:5) 220±52 273±15 -18±2 -19±3 
     
0.1CMC F87(1:10) 863±14 419±14 -12.6±7 -45±6 
1 CMC F87 (1:10) 426±2.7 579±12 -23±3 -26±0.5 
2 CMC F87 (1:10) 393±19 284±16 -14±2 -17±2 
 
 
Table  3-9 Particle Size and Zeta Potential of Pluronic F108+D+GS and F108+D+GS+DNA 
GS=Gemini Surfactant, D=DOPE 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F801+D+GS   F801+D+GS+DNA       F801+D+GS F801+D+GS+DNA 
     
0.1 CMC F801(1:2) 447±25 481±34 -5±0.3 -14.5±1.73 
1 CMC F801(1:2) 232±20 355±20 -6±0.7 -2±1.4 
2 CMC F801(1:2) 432±37 3196±938 -6±0.8 -15.6±1.9 
     
0.1 CMC F801(1:5) 230±25 780±153 -5±0.5 -16±2.7 
1 CMC F801 (1:5) 628±221 2268±45 -5.5±0.5 -8±6.5 
2 CMC F801 (1:5) 820±52 1010±471 -6.6±0.9 -2±1 
     
0.1CMCF801(1:10) 767±43 1079±361 -0.01±0.4 0.005±0.4 
1 CMC F801 (1:10) 671±0.3 2501±68 -5±0.7 -3±0.9 
2 CMC F801 (1:10) 977±78 2017±311 -4.8±0.2 -1.5±0.9 
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Table  3-10 Particle Size and Zeta Potential of Pluronic F127+D+GS and F127+D+GS+DNA 
GS=Gemini Surfactant, D=DOPE 
Pluronic  Size(nm) 
            
    ζ-Potential(mV)  
 F827+D+GS   F827+D+GS+DNA       F827+D+GS F827+D+GS+DNA 
     
0.1 CMC F827(1:2) 785±235 2844±380 -5±1.15 -24±12 
1 CMC F827(1:2) 783±35 1487±628 -5±0.13 -18±7 
2 CMC F827(1:2) 802±71 491±16 -4±0.7 -11±8 
 
    0.1 CMC F827(1:5) 984±125 2350±102 -5±1 -14±5 
1 CMC F827 (1:5) 743±67 1986±533 -5.5±0.9 -11±5 
2 CMC F827 (1:5) 829±39 504±8 -4.5±0.7 -0.05±0.05 
 
    0.1CMCF827(1:10) 1116±94 1549±109 -5.5±0.8 11.4±12 
1 CMC F827 (1:10) 960±90 1183±46 -5±0.6 37±1.4 
2 CMC F827 (1:10) 1138±348 793±133 -6±1 16±4.5 
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Figure  3.4  Zeta Potential of the Pluronics at ratio 1: 2 A) Zeta potential of the Pluronics at 0.1, 1, 
and 2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation.  
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Figure  3.5  Zeta Potential of the Pluronics at ratio 1: 5 A) Zeta potential of the Pluronics at 0.1, 1, 
and 2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation.  
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Figure  3.6  Zeta Potential of the the Pluronics at ratio 1: 10 A) Zeta potential of the Pluronics at 
0.1, 1, and 2 CMC in combination with gemini surfactant (16-3-16) and DNA. B) As in A) with 
DOPE. Results are shown as mean (n=3), errors bars represent standard deviation. 
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3.2 Evaluate the efficiency of GFP expression of gemini surfactant/pluronics-based nano-
particles on OVCAR-3 cell culture in presence and absence of helper lipid (DOPE) 
OVCAR-3 cell line was transfected using Pluronic-GS-DNA complex in both absence and pres-
ence of DOPE. Three concentrations (0.1, 1, and 2 CMC) of all five Pluronics (L44, F68, F87, 
F108, and F127) were used in this project. GS 16-3-16 was added at three different ratios to DNA 
(2:1, 5:1, and 10:1). After that, DOPE was added to Pluronics to examine if it has any effect on 
transfection efficiency. OVCAR-3 cell line was transfected with these complexes and the results 
were determined using FACS analysis. Figure 3.7 elucidates the way in which the results were 
analyzed. The Plot graph is divided into four squares. The upper left corner shows dead cells on-
ly. Live cells are shown in the lower left corner. GFP expression is shown in the lower right cor-
ner, while the upper right corner represents the transfected dead cells.   
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Figure  3.7 Analysis of Transfection experiments using FACS 
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Bar graphs below indicate the results of these transfections. The maximum fluorescent 
emission was observed with these three Pluronics (L44, F87, and F108); when the weight ratio of 
DNA: GS was 1:5; the transfection efficiency reached as much as 15% comparing to Lipofec-
tamine® 2000. Pluronic F127 obtained the lowest transfection efficiency among all Pluronics. 
Interestingly, the highest transfection efficiency of Pluronic F68 was observed when the ratio 
DNA: GS was 1:10. It was also clear from these results that the CMC of Pluronics did not have 
much effect on transfection. It is evident that all CMC (0.1, 1. and 2) have the ability to transfect 
OVCAER-3 cells at different ratios or Pluronics. Adding helper lipid (DOPE) did not improve the 
transfection efficiency of the five Pluronics.  
No transfection was observed for the combination of Pluronics with DNA alone. That 
was expected as there was no compaction with DNA (data not shown). As a result, a cationic 
gemini surfactant plays a very significant role to improve the transfection efficiency of Pluronics. 
A positive surface charge is necessary for attachment to the anionic cell surface and compaction 
with DNA, which facilitates the entering of polyplexes into cells by cellular uptake 87. The most 
likely reason for the low transfection efficiency of Pluronics with DOPE was because of the poor 
compaction with DNA as well as with the cell surface.  
It is evident from the results is that the highest transfection was noticed with a charge ra-
tio of 1:5 for all Pluronics except Pluronics F68. These results indicated that there was a strong 
compaction in this ratio. Low transfection efficiency with ratio 1:2 was probably due to the weak 
interaction between the cationic surfactant and DNA. At the same time, high toxicity at ratio 1:10 
occurred because of large additions of gemini surfactant may led to low transfection efficiency.                
Generally, to investigate the correlation between molecular weight and transfection effi-
ciency, it is clear from the results that the molecular weight did not influence the transfection re-
sults. For example, F108 has the largest molecular weight (Mw=14600) among all five Pluronics; 
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however, it transfected OVCAR-3 cell line effectively. On the other hand, F127 which also has a 
large molecular weight (Mw= 12600) obtained the lowest transfection efficiency. Cherve et al.  
verified these findings when they obtained a similar luciferase expression for three different Plu-
ronics (P85, F68, and F108), although they have three different molecular weights ranging from 
4600 to 14600 Da 60.  
In addition, the relationship between hydrophilic-lipophilic balance (HLB) and transfec-
tion efficiency was studied by Sriadibhatla et al 63. They found that copolymers that have inter-
mediate HLB (9-16), and relatively large hydrophobic blocks (30-69 PO units) were the most ef-
fective. They also found that copolymers with short PO units such as L35 (16 PO units), and hy-
drophilic copolymers such as F127 (HLB 22), were less effective. In contrast to these results, our 
findings show that F87 and F108 which have high HLB (24, 27) obtained transfection efficiency 
similar to L44 (HLB 16). These results were proven by Cherve and colleagues when they found 
that F68, with the highest HLB (29), was able to increase luciferase expression. This was similar 
to P85, which has intermediate HLB (16) 60. They also concluded that Pluronic block copolymers 
do not enhance nucleic acid transfection at the same level, and they agreed with the previous data 
obtained by Batrakova et al.57 which indicated that polymer structure affects the cell membrane 
interaction behavior and signaling pathway activation.  
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Figure  3.8 In vitro Transfection of OVCAR-3 Cells Contain Pluronic L44 
A) In vitro transfection of OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic L44 in combination 
with plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation.  
A 
P<0.001 
B 
P<0.001 
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Figure  3.9 In vitro transfection of OVCAR-3 Cells Contains Pluronic F68 
A) In vitro transfection of OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F68 in combination 
with plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation.  
A 
B 
P<0.001 
P<0.001 
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Figure  3.10 In vitro transfection of OVCAR-3 Cells Contains Pluronic F87 
A) In vitro transfection of OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F87 in combination 
with plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in A) with DOPE. 
Results are shown as mean (n=3), errors bars represent standard deviation.  
P<0.001 
P<0.001 
A 
B 
  50  
 
              0.1 CMC                             1 CMC                              2 CMC 
Lipofectamine 1 : 2 1 : 5 1 : 10
E
G
F
P
 E
x
p
re
ss
io
n
 (
%
) 
in
 O
V
C
A
R
-3
 C
el
ls
1
10
100
 
Lipofectamine 1 : 2 1 : 5 1 : 10
E
G
F
P
 E
x
p
re
ss
io
n
 (
%
) 
in
 O
V
C
A
R
-3
 C
el
ls
0.1
1
10
100
 
 Figure  3.11 In vitro transfection of OVCAR-3 Cells Contains Pluronic F108 
A) In vitro transfection of OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F108 in combi-
nation  with plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in 
A) with DOPE. Results are shown as mean (n=3), errors bars represent standard deviation 
  
P<0.001 
P<0.001 
A 
B 
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Figure  3.12 In vitro transfection of OVCAR-3 Cells Contains Pluronic F127 
A) In vitro transfection of OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F127 in combi-
nation with plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in A) 
with DOPE. Results are shown as mean (n=3), errors bars represent standard deviation.  
A 
B 
P<0.001 
P<0.001 
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3.3 Evaluate the Cytotoxicity of these complexes on OVCAR-3 cell culture in presence and 
absence of helper lipid (DOPE) by adding Propidium Iodide (PI)   
Regarding cell viability, this project aimed to study the cytotoxicity of Pluronic-GS-DNA com-
plex after it transfects in OVCAR-3 cell line in the presence and absence of DOPE. The same 
protocol of transfection was used with cell viability up to the last step. Then, 10 uL of propidium 
iodide was added to examine the cell death. The results were determined using FACs analysis.  
According to Bieber and colleagues, there is a correlation between cytotoxicity and mo-
lecular weight 88. Lungwits et al.  also reported that high molecular weight PEI has significantly 
more cytotoxicity than low molecular weight PEI 89. Therefore, it can be noticed, as seen in Table 
1-1, that Pluronics F108 and F127 have high molecular weights (Mw= 14600 and 12600). As a 
result, the lowest cell viability was shown with Pluronics F108 and F127, particularly after adding 
DOPE. 
 It is also clear, as seen in the bar graphs below, that cell viability decreases when the 
amount of gemini surfactant increases. In OVCAR-3 cell line, the Pluronic-GS-DNA complex 
shows about 70% cell viability at ratio 1:2, indicating that Pluronics were essentially non-toxic at 
the concentration used in gene therapy 60.  
Adding DOPE to the Pluronics did not improve cell viability. Bar graphs below show the 
cell viability after adding DOPE. Pluronics at all three ratios have cell viability higher than Plu-
ronics that contain DOPE, except for Pluronic F68. Positive control (Lipofectamine® 2000) ob-
tained the lowest cell viability for approximately 32%.   
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Figure  3.13 Cell Viability of OVCAR-3 Cells Contain Pluronic L44 
A) Cell viability OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic L44 in combination with 
plasmid DNA and gemini surfactant with ratio 1:2, 1:5, and 1:10. B) As in A) with 
DOPE. Results are shown as mean (n=3), errors bars represent standard deviation.  
 
P<0.001 
P<0.001 
B 
A 
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Figure  3.14 Cell Viability of OVCAR-3 Cells Contain Pluronic F68 
A) Cell viability OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F68 in combination with 
plasmid DNA and gemini surfactant with Ratio 1:2, 1:5, and 1:10. B) As in A) with DOPE. Re-
sults are shown as mean (n=3), errors bars represent standard deviation.  
 
P<0.001 
P<0.001 
B 
A 
  55  
                  0.1 CMC                               1 CMC                             2 CMC  
NT Lipofectamine 1 : 2 1 : 5 1 : 10
C
el
l 
V
ia
b
il
it
y
 (
%
) 
in
 O
V
C
A
R
-3
 C
el
ls
 
10
100
 
NT Lipofectamine 1 : 2 1 : 5 1 : 10
C
el
l 
V
ia
b
il
it
y
 (
%
) 
in
 O
V
C
A
R
-3
 c
el
ls
10
100
 
Figure  3.15 Cell Viability of OVCAR-3 Cells Contain Pluronic F87 
A) Cell viability OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F87 in combination with 
plasmid DNA and gemini surfactant with Ratio 1:2, 1:5, and 1:10. B) As in A) with 
DOPE. Results are shown as mean (n=3), errors bars represent standard deviation. 
 
B 
P<0.001 
A 
P<0.001 
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Figure  3.16 Cell Viability of OVCAR-3 Cells Contain Pluronic F108 
A) Cell viability OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F108 in combination with 
plasmid DNA and gemini surfactant with Ratio 1:2, 1:5, and 1:10. B) As in A) with 
DOPE. Results are shown as mean (n=3), errors bars represent standard deviation.  
 
A 
B 
P<0.001 
P<0.001 
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Figure  3.17 Cell Viability of OVCAR-3 Cells Contain Pluronic F127 
A) Cell viability OVCAR-3 cells with 0.1, 1, and 2 CMC Pluronic F127 in combination with 
plasmid DNA and gemini surfactant with Ratio 1:2, 1:5, and 1:10. B) As in A) with DOPE. Re-
sults are shown as mean (n=3), errors bars represent standard deviation.  
 
A 
B 
P<0.001 
P<0.001 
  
 58 
 
Chapter 4 
Conclusion and Future Works 
This project investigated the transfection efficiency and cytotoxicity of five Pluronic block copoly-
mers (L44, F68, F87, F108, and F127) in combination with gemini surfactant 16-3-16 at 1.5 mM in 
OVCAR-3 cell line. Three concentrations of copolymers were used (0.1, 1, and 2 cmc), and three ra-
tios of DNA to gemini surfactant were tested (1:2, 1:5, and 1:10). Physiochemical properties that in-
clude particle size and zeta potential of Pluronic-GS-DNA complexe were studied. DOPE was added 
with all five Pluronics to examine if it has any effect on transfection efficiency.  
 The findings of this project showed that all five Pluronics were able to transfect OVCAR-3 
cell line with various percentages. Ratio 1:5 obtained the highest transfection efficiency for all Plu-
ronics except F68. F127 obtained the lowest transfection efficiency among all five Pluronics. L44, 
F87, and F108 achieved similar transfection efficiency. Adding DOPE to these Pluronics did not im-
prove transfection efficiency. Cytotoxicity increased with increasing amounts of gemini surfactant, 
suggesting that copolymers are non-toxic.  
Suggesting for future study would be examined more Pluronics in addition to these used in 
this project. In particular, Pluronics that have intermediate HLB such as L64, P85, and P103 should 
be examined to verify the findings of Sriadibhatla and colleagues who claimed that Pluronics with 
intermediate HLB (9-16) are the most effective 63.  
Another study that would be worthy is to examine different classes of gemini surfactants in 
addition to m-s-m class that was used in this study. Shawn and colleagues have found that gemini sur-
factnts that have  s ≤ 4 or s > 12 showed the greatest transfection efficiency, e.g. 16-2-16 18. Also, the 
amine-substitute spacer gemini surfactants such as 12-7NH-12 showed very high transfection effi-
ciency versus 12-5N-12, 12-7N12, and 12-8N-12 18. It would be worthwhile to examine these gemini 
surfactants with Pluronics. In addition, phytanyl-substituted gemini surfactants, such as phy-3-16 and 
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phy-3-18 could be another effective alternatives, demonstrated by Wang and Wettig 90. These might 
be used with Pluronics in a future study.  
The transfection efficiency did not improve after adding helper lipid (DOPE) in this study. 
Thus, changing the concentration of DOPE to be appropriate with the concentration of Pluronics 
might be a helpful technique that leads to transfection improvement. Also, using DOPE with different 
gemini surfactants other than 16-3-16 may improve transfection efficiency.  
Finally, the most important study that will be worthy of investigation is to examine these Plu-
ronics in vivo, as many experiments in the existing literature approved the transfection efficiency in 
vivo 60. Pluronics alone were able to improve transfection efficiency in vivo; consequently, trying Plu-
ronics with gemini surfactants or with gemini surfactants and DOPE will constitute another interest-
ing study that might improve the transfection.  
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Appendix A 
 
Table  4-1 physical properties of pluronics used in this study.  Adapted from product technical infor-
mation sheets available from the product manufacturer, BASF 
 
Pluronic 
Surfactant  
Polaxo-
mer name 
Chemical Structure Specific 
gravity 
Melt 
point 
 
Form  Solubility in 
water at 25 ºC 
L44NF 124 HO(C2H4O)12(C3H6O)20(C2H4O)12H 1.05 16 ºC Liquid  ˃10% 
F68NF 188 HO(C2H4O)80(C3H6O)27(C2H4O)80H 1.06 52 ºC Prill ˃10% 
F87NF 237 HO(C2H4O)64(C3H6O)37(C2H4O)64H 1.04 49 ºC Prill ˃10% 
F108NF                   338 
 
HO(C2H4O)141(C3H6O)44(C2H4O)141H 1.06 57 ºC Prill ˃10% 
F127NF                 
407 
HO(C2H4O)101(C3H6O)56(C2H4O)101H 1.05 56 ºC Prill ˃10% 
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Appendix B 
Table  4-2 Transfection Results of L44±SD 
 
 
 GFP-
_PI- 
GFP+ PI+ GFP+_PI+  SD GFP-
_PI- 
GFP+ PI+ GFP+_PI+ 
NT 97.9883 0.197798 1.266863 0.547033  NT 0.242762 0.039487 0.212842 0.0629 
NT+PI 79.95 0.191667 19.275 0.583333  NT+PI 1.256732 0.166458 1.002809 0.112731 
L+p 67.625 24.64167 1.8 5.933333  L+P 0.803508 1.341951 0.108972 0.707254 
L+P+PI 32.88333 25.90833 23.21667 17.99167  L+P+PI 1.322009 0.465251 1.223809 0.659703 
0.1(2) 72.68333 0.008333 27.10833 0.2  0.1(2) 1.8842 0.014434 1.846844 0.025 
1(2) 71.49167 0.025 28.28333 0.2  1(2) 1.167886 0.025 1.075388 0.090139 
2(2) 69.81667 0.033333 29.75833 0.391667  2(2) 0.483692 0.014434 0.448841 0.072169 
0.1(5) 43.625 12.1 33.925 10.35  0.1(5) 0.7587 0.520216 0.303109 0.828779 
1(5) 51.49167 4.625 41.59167 2.291667  1(5) 0.038188 0.2 0.125831 0.112731 
2(5) 49.98333 3.875 43.85 2.291667  2(5) 1.176418 0.175 1.231868 0.125831 
0.1(10) 44.40833 1.033333 53.36667 1.191667  0.1(10) 0.687538 0.101036 0.673764 0.062915 
1(10) 40.45 0.716667 57.65833 1.175  1(10) 1.297112 0.175594 1.499236 0.108972 
2 (10) 42.975 0.775 55.375 0.875  2(10) 1.167529 0.217945 0.992157 0.132288 
D1(2) 55.41667 5.483333 34.55833 4.541667  D1(2) 0.361709 0.189297 0.704598 0.401819 
D2(2) 58.4 2.816667 36.325 2.458333  D2(2) 0.492443 0.34126 0.606733 0.312583 
D3(2) 51.58333 2.325 44.00833 2.083333  D3(2) 0.837531 0.15 0.929157 0.112731 
D1(5) 51.94167 4.075 41.46667 2.516667  D1(5) 1.179601 0.204634 1.041733 0.312583 
D2(5) 52.56667 4.358333 40.51667 2.558333  D2(5) 0.54448 0.425979 1.0153 0.076376 
D3(5) 55.31667 3.883333 38.63333 2.166667  D3(5) 0.52698 0.284312 1.221253 0.418579 
D1(10) 42.14167 1.291667 55.30833 1.258333  D1(10) 1.115329 0.337577 0.850123 0.052042 
D2(10) 41.31667 1.075 56.69167 0.916667  D2(10) 1.006955 0.086603 1.038127 0.209662 
D3(10) 43.19167 0.8 55.01667 0.991667  D3(10) 0.592839 0.129904 0.65208 0.087797 
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Table ‎4-3 Transfection Results of F68±SD 
 
 
 PI+ GFP+_PI+ GFP-
_PI- 
GFP+ SD PI+ PI+_GFP+ PI-
_GFP- 
GFP+ 
NT 0 0.011111 99.9333 0.055556 NT 0 0.019245 1.74E-14 0.019245 
NT+PI 22.56666667 0.122222 77.22223 0.088889 NT+PI 1.682594 0.069389 1.756375 0.050917 
L+p 0.077777667 6.044447 49.14443 44.73333 L+P 0.050917 0.226893 1.302276 1.13335 
L+P+PI 11.86666667 15.13333 35.1778 37.8222 L+P+PI 0.317981 0.338308 1.486738 1.392979 
0.1(2) 24.82223333 0.177778 74.43333 0.566667 0.1(2) 0.822163 0.069389 0.737111 0.088192 
1(2) 32.8222 0.222222 66.64443 0.311111 1(2) 0.523173 0.101835 0.250186 0.195315 
2(2) 62.77776667 0.233333 36.76667 0.222222 2(2) 0.855285 0.057735 0.856973 0.117063 
0.1(5) 51.9889 1.033332 45.52223 1.455557 0.1(5) 0.686614 0.272843 0.661946 0.138779 
1(5) 43.2778 0.488889 55.1 1.133333 1(5) 0.725968 0.019245 0.788111 0.088189 
2(5) 32.64446667 0.255556 66.74443 0.355555 2(5) 0.661946 0.083887 0.600293 0.03849 
0.1(10) 29.19996667 6.08889 54.5 10.21112 0.1(10) 1.289703 0.234122 0.433335 1.252708 
1(10) 27.2889 4.91111 59.30003 8.5 1(10) 1.35168 0.117061 1.457166 0.504427 
2 (10) 30.9222 2.655557 60.97777 5.444443 2(10) 0.346958 0.101836 0.350131 0.050918 
D1(2) 24.35556667 0.122222 74.95553 0.566667 D1(2) 0.776249 0.03849 0.567012 0.233333 
D2(2) 44.6889 0.488889 54.1778 0.644445 D2(2) 0.90207 0.183586 0.816707 0.107152 
D3(2) 45.18886667 0.277778 54.25557 0.277778 D3(2) 1.07977 0.083887 0.91794 0.117063 
D1(5) 30.9889 0.222222 68.3222 0.466667 D1(5) 0.504815 0.083887 0.424711 0.066667 
D2(5) 27.5778 0.899999 69.84443 1.67778 D2(5) 1.160638 0.152751 1.295041 0.019243 
D3(5) 30.17776667 0.355556 68.85557 0.611111 D3(5) 0.778442 0.083887 0.870041 0.107152 
D1(10) 21.73333333 2.455553 69.0889 6.72222 D1(10) 0.683961 0.302459 0.101831 0.316811 
D2(10) 19.92223333 4.5 65.7 9.877767 D2(10) 0.350131 0.218579 0.491059 0.167759 
D3(10) 20.64446667 2.73333 69.21113 7.41111 D3(10) 0.467047 0.264575 1.128088 0.619439 
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Table  4-4 Transfection Results of F87±SD 
 
 
 
 PI+ GFP+_PI+ GFP-_PI- GFP+ SD PI+ GFP+PI+ GFP-_PI- GFP+ 
NT 0.077778 0.566667 99.04447 0.311111 NT 0.050917 0.145297 0.038509 0.101835 
NT+PI 18.42223 0.822222 80.37777 0.377778 NT+PI 0.607661 0.226895 0.482257 0.107152 
L+p 5.37778 14.84447 40.6889 39.0889 L+p 0.183585 0.691501 0.554112 0.81127 
L+P+PI 13.65557 23.60003 29.6778 33.06667 L+P+PI 0.616775 0.503322 1.098667 1.32961 
0.1(2) 24.67777 5.733333 62.59997 6.98889 0.1(2) 0.795394 0.384418 0.776745 0.365655 
1(2) 19.04447 8.622223 60.7111 11.6222 1(2) 0.78624 0.485719 0.802981 1.039428 
2(2) 41.97777 2.38889 52.54443 3.08889 2(2) 0.976039 0.283498 1.403304 0.397675 
0.1(5) 28.25553 7.733333 54.34443 9.666643 0.1(5) 0.552099 0.233331 0.872027 1.078562 
1(5) 32.66667 8.388887 48.02223 10.92223 1(5) 0.491001 0.657719 0.947688 0.269466 
2(5) 29.05553 13.05553 43.1889 14.7 2(5) 0.81126 0.82754 1.387342 0.523879 
0.1(10) 43.1889 3.144447 50.3 3.366667 0.1(10) 1.120178 0.279551 1.189331 0.233335 
1(10) 45.5222 3.8 45.82223 4.855553 1(10) 0.80025 0.43589 0.221973 0.291231 
2 (10) 51.4889 3.7 41.35557 3.455557 2 (10) 1.512276 0.176383 1.378547 0.416781 
D1(2) 21.57777 9.833333 55.56667 13.0222 D1(2) 0.633643 0.145297 0.338264 0.443903 
D2(2) 21.03337 6.244443 61.7222 11.00003 D2(2) 0.64291 0.462282 1.011785 0.152753 
D3(2) 21.1 6.733333 59.0111 13.15557 D3(2) 1.155153 0.504422 1.607392 0.416812 
D1(5) 37.12223 6.01111 49.21113 7.655553 D1(5) 0.567954 0.183587 0.567955 0.422074 
D2(5) 30.02223 7.455557 51.9111 10.6111 D2(5) 0.435077 0.379086 0.459846 0.636238 
D3(5) 57.8 4.955557 30 7.244443 D3(5) 0.202729 0.455017 0.536469 0.342103 
D1(10) 46.22223 3.177777 46.24447 4.355557 D1(10) 0.42207 0.134717 0.234143 0.083884 
D2(10) 68.77777 2.866667 26.63333 1.722223 D2(10) 0.518933 0.260344 0.536463 0.279551 
D3(10) 64.9111 3.566667 28.36667 3.155557 D3(10) 0.806443 0.378594 0.44099 0.200924 
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Table  4-5 Transfection Results of F108±SD 
 
 PI+ GFP+_PI+ GFP-
_PI- 
GFP+ SD PI+ GFP+_PI+ GFP-
_PI- 
GFP+ 
NT 0.044444 0 99.95557 0 NT 0.07698 0 0.076961 0 
NT+PI 27.55557 0.011111 72.43333 0 NT+PI 0.450103 0.019245 0.46665 0 
L+p 1.366667 4.5 60.03333 34.1 L+p 0.384421 0.33333 0.40549 0.433335 
L+P+PI 23.03337 11.24443 37.92223 27.8 L+P+PI 1.069268 0.683368 0.389221 0.793725 
0.1(2) 35.2111 0.477778 62.4778 1.833333 0.1(2) 0.625714 0.101835 0.716714 0.176387 
1(2) 29.34443 0.255555 68.8889 1.511113 1(2) 0.857842 0.134715 0.883391 0.250183 
2(2) 48.59997 0.844444 48.2889 2.26667 2(2) 0.550757 0.117063 0.422088 0.1 
0.1(5) 32.36667 3.2 57.7333 6.700003 0.1(5) 1.065079 0.371183 0.655744 0.288675 
1(5) 33.24443 7.166667 45.35557 14.23333 1(5) 0.518886 0.80898 0.46229 0.762281 
2(5) 31.30003 6.011113 48.51113 14.1778 2(5) 1.625833 0.214303 1.526202 0.416761 
0.1(10) 53.0222 1.788887 41.65553 3.533333 0.1(10) 0.283513 0.423388 0.433778 0.208167 
1(10) 50.65553 1.7 44.17777 3.46667 1(10) 0.661931 0.317983 0.699508 0.264575 
2 (10) 50.16667 2.066667 41.8889 5.877777 2 (10) 0.484161 0.384415 0.379064 0.36717 
D1(2) 49.13333 0.077778 50.65553 0.133333 D1(2) 1.125989 0.050917 1.281188 0.133334 
D2(2) 69.3 0.311111 30.0889 0.3 D2(2) 0.876224 0.050918 0.774855 0.120185 
D3(2) 72.05557 0.177778 27.55553 0.211111 D3(2) 0.236502 0.050917 0.267344 0.083887 
D1(5) 43.75553 6.144447 40.86667 9.233333 D1(5) 0.885914 0.20367 1.549585 0.569604 
D2(5) 56.45553 5.722223 29.3667 8.455557 D2(5) 0.895267 0.221947 1.044031 0.597524 
D3(5) 60.76667 3.455553 29.71113 6.066663 D3(5) 0.968371 0.107152 1.014531 0.251661 
D1(10) 60.33333 1.28889 36.16667 2.21111 D1(10) 0.03335 0.183587 0.328287 0.16443 
D2(10) 62.95557 2.744443 29.7 4.6 D2(10) 0.907619 0.150308 0.409633 0.523878 
D3(10) 84.04147 1.37013 13.2892 1.299173 D3(10) 0.430401 0.376792 0.60433 0.154101 
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Table ‎4-6 Transfection Results of F127±SD  
 
 GFP-_PI- GFP+ PI+ GFP+_PI+ SD GFP-_PI- GFP+ PI+ GFP+_PI+ 
NT 96.6406 0.227354 1.96944 1.162605 NT 0.467822 0.119496 0.522467 0.174097 
NT+PI 76.8762 0.12381 22.13333 0.866667 NT+PI 0.412401 0.167413 0.649826 0.11547 
L+P 39.61907 43.42857 0.69524 16.25713 L+P 1.371808 1.004884 0.380478 0.993435 
L+P+PI 29.8 29.85717 16.1619 24.18093 L+P+PI 0.974774 0.915616 0.25605 0.934722 
0.1 (2) 47.90477 2.04762 46.80953 3.238097 0.1 (2) 1.388652 0.256084 1.603668 0.239617 
1 (2) 57.89523 0.028571 41.05717 1.019048 1 (2) 0.416352 0.028571 0.645846 0.340867 
2 (2) 35.78097 0 63.2857 0.933334 2 (2) 1.117702 0 1.330621 0.396242 
0.1 (5) 38.29523 2.933333 54.06667 4.70476 0.1 (5) 0.775846 0.300113 0.474922 0.131965 
1(5) 23.71427 0.4 71.6 4.285717 1(5) 0.830076 0.049487 1.14139 0.426662 
2 (5) 24.6476 0.8 70.73333 3.819047 2 (5) 0.518516 0.114286 0.380453 0.174575 
0.1(10) 25.69523 0.009524 61.99047 12.30477 0.1(10) 0.157344 0.016496 0.512158 0.651697 
1  (10) 33.01907 1.885713 59.81903 5.276193 1  (10) 1.097773 0.298294 1.36349 0.405406 
2  (10) 34.1905 1.980953 59.1905 4.638093 2  (10) 0.757195 0.118956 0.657978 0.016495 
D1 (2) 55.61907 0.114286 43.09523 1.171431 D1 (2) 1.665334 0.049487 1.982827 0.272556 
D2 (2) 39.0381 0.066667 60.04763 0.847619 D2 (2) 0.73974 0.043644 0.945163 0.185897 
D3 (2) 48.00953 3.46667 41.00953 7.514287 D3 (2) 0.483494 0.293235 0.462791 0.364778 
D1 (5) 39.82857 4.24762 49.9048 6.019043 D1 (5) 0.54515 0.246337 0.603618 0.305505 
D2(5) 43.50437 0.015657 54.90133 1.578653 D2(5) 1.543187 0.027118 1.71568 0.296621 
D3(5) 37.10477 4.085713 51.20953 7.6 D3(5) 1.105561 0.336851 1.573815 0.347586 
D1 (10) 29.8857 0.866667 61.1714 8.07619 D1(10) 1.045488 0.206691 0.965963 0.334825 
D2 (10) 20.99047 1.07619 72.2 5.733337 D2(10) 0.087276 0.242999 0.426654 0.385803 
D3 (10) 18.80953 0.628571 72.84763 7.714283 D3(10) 0.635274 0.098974 0.71391 0.831522 
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Appendix C         
 
  
25.900 .790 <.0001 S
25.883 .790 <.0001 S
25.875 .790 <.0001 S
13.808 .790 <.0001 S
21.283 .790 <.0001 S
22.033 .790 <.0001 S
24.875 .790 <.0001 S
25.192 .790 <.0001 S
25.133 .790 <.0001 S
-.017 .790 .9369
-.025 .790 .9054
-12.092 .790 <.0001 S
-4.617 .790 <.0001 S
-3.867 .790 <.0001 S
-1.025 .790 <.0001 S
-.708 .790 .0028
-.767 .790 .0014
-.008 .790 .9684
-12.075 .790 <.0001 S
-4.600 .790 <.0001 S
-3.850 .790 <.0001 S
-1.008 .790 <.0001 S
-.692 .790 .0033
-.750 .790 .0017
-12.067 .790 <.0001 S
-4.592 .790 <.0001 S
-3.842 .790 <.0001 S
-1.000 .790 .0001 S
-.683 .790 .0037
-.742 .790 .0019
7.475 .790 <.0001 S
8.225 .790 <.0001 S
11.067 .790 <.0001 S
11.383 .790 <.0001 S
11.325 .790 <.0001 S
.750 .790 .0017
3.592 .790 <.0001 S
3.908 .790 <.0001 S
3.850 .790 <.0001 S
2.842 .790 <.0001 S
3.158 .790 <.0001 S
3.100 .790 <.0001 S
.317 .790 .1431
.258 .790 .2280
-.058 .790 .7817
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2(0.1CMC)
Lipofectamine, 1:2(1CMC)
Lipofectamine, 1:2(2CMC)
Lipofectamine, 1:5(0.1CMC)
Lipofectamine, 1:5(1CMC)
Lipofectamine, 1:5(2CMC)
Lipofectamine, 1:10(0.1C...
Lipofectamine, 1:10(1CMC)
Lipofectamine, 1:10(2CMC)
1:2(0.1CMC), 1:2(1CMC)
1:2(0.1CMC), 1:2(2CMC)
1:2(0.1CMC), 1:5(0.1CMC)
1:2(0.1CMC), 1:5(1CMC)
1:2(0.1CMC), 1:5(2CMC)
1:2(0.1CMC), 1:10(0.1CMC)
1:2(0.1CMC), 1:10(1CMC)
1:2(0.1CMC), 1:10(2CMC)
1:2(1CMC), 1:2(2CMC)
1:2(1CMC), 1:5(0.1CMC)
1:2(1CMC), 1:5(1CMC)
1:2(1CMC), 1:5(2CMC)
1:2(1CMC), 1:10(0.1CMC)
1:2(1CMC), 1:10(1CMC)
1:2(1CMC), 1:10(2CMC)
1:2(2CMC), 1:5(0.1CMC)
1:2(2CMC), 1:5(1CMC)
1:2(2CMC), 1:5(2CMC)
1:2(2CMC), 1:10(0.1CMC)
1:2(2CMC), 1:10(1CMC)
1:2(2CMC), 1:10(2CMC)
1:5(0.1CMC), 1:5(1CMC)
1:5(0.1CMC), 1:5(2CMC)
1:5(0.1CMC), 1:10(0.1CMC)
1:5(0.1CMC), 1:10(1CMC)
1:5(0.1CMC), 1:10(2CMC)
1:5(1CMC), 1:5(2CMC)
1:5(1CMC), 1:10(0.1CMC)
1:5(1CMC), 1:10(1CMC)
1:5(1CMC), 1:10(2CMC)
1:5(2CMC), 1:10(0.1CMC)
1:5(2CMC), 1:10(1CMC)
1:5(2CMC), 1:10(2CMC)
1:10(0.1CMC), 1:10(1CMC)
1:10(0.1CMC), 1:10(2CMC)
1:10(1CMC), 1:10(2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for TE
Effect: Column 1
Significance Level: 5 %
Table  4-7 Pluronic L44 Anova statistics 
TE= Transfection Effeciency 
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-39.800 3.456 <.0001 S
-38.608 3.456 <.0001 S
-36.933 3.456 <.0001 S
-10.742 3.456 <.0001 S
-18.608 3.456 <.0001 S
-17.100 3.456 <.0001 S
-11.525 3.456 <.0001 S
-7.567 3.456 <.0001 S
-10.092 3.456 <.0001 S
1.192 3.456 .2044
2.867 3.456 .0050
29.058 3.456 <.0001 S
21.192 3.456 <.0001 S
22.700 3.456 <.0001 S
28.275 3.456 <.0001 S
32.233 3.456 <.0001 S
29.708 3.456 <.0001 S
1.675 3.456 .0800
27.867 3.456 <.0001 S
20.000 3.456 <.0001 S
21.508 3.456 <.0001 S
27.083 3.456 <.0001 S
31.042 3.456 <.0001 S
28.517 3.456 <.0001 S
26.192 3.456 <.0001 S
18.325 3.456 <.0001 S
19.833 3.456 <.0001 S
25.408 3.456 <.0001 S
29.367 3.456 <.0001 S
26.842 3.456 <.0001 S
-7.867 3.456 <.0001 S
-6.358 3.456 <.0001 S
-.783 3.456 .3987
3.175 3.456 .0023
.650 3.456 .4825
1.508 3.456 .1124
7.083 3.456 <.0001 S
11.042 3.456 <.0001 S
8.517 3.456 <.0001 S
5.575 3.456 <.0001 S
9.533 3.456 <.0001 S
7.008 3.456 <.0001 S
3.958 3.456 .0003 S
1.433 3.456 .1302
-2.525 3.456 .0116
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2(0.1CMC)
Lipofectamine, 1:2(1CMC)
Lipofectamine, 1:2(2CMC)
Lipofectamine, 1:5(0.1CMC)
Lipofectamine, 1:5(1CMC)
Lipofectamine, 1:5(2CMC)
Lipofectamine, 1:10(0.1C...
Lipofectamine, 1:10(1CMC)
Lipofectamine, 1:10(2CMC)
1:2(0.1CMC), 1:2(1CMC)
1:2(0.1CMC), 1:2(2CMC)
1:2(0.1CMC), 1:5(0.1CMC)
1:2(0.1CMC), 1:5(1CMC)
1:2(0.1CMC), 1:5(2CMC)
1:2(0.1CMC), 1:10(0.1CMC)
1:2(0.1CMC), 1:10(1CMC)
1:2(0.1CMC), 1:10(2CMC)
1:2(1CMC), 1:2(2CMC)
1:2(1CMC), 1:5(0.1CMC)
1:2(1CMC), 1:5(1CMC)
1:2(1CMC), 1:5(2CMC)
1:2(1CMC), 1:10(0.1CMC)
1:2(1CMC), 1:10(1CMC)
1:2(1CMC), 1:10(2CMC)
1:2(2CMC), 1:5(0.1CMC)
1:2(2CMC), 1:5(1CMC)
1:2(2CMC), 1:5(2CMC)
1:2(2CMC), 1:10(0.1CMC)
1:2(2CMC), 1:10(1CMC)
1:2(2CMC), 1:10(2CMC)
1:5(0.1CMC), 1:5(1CMC)
1:5(0.1CMC), 1:5(2CMC)
1:5(0.1CMC), 1:10(0.1CMC)
1:5(0.1CMC), 1:10(1CMC)
1:5(0.1CMC), 1:10(2CMC)
1:5(1CMC), 1:5(2CMC)
1:5(1CMC), 1:10(0.1CMC)
1:5(1CMC), 1:10(1CMC)
1:5(1CMC), 1:10(2CMC)
1:5(2CMC), 1:10(0.1CMC)
1:5(2CMC), 1:10(1CMC)
1:5(2CMC), 1:10(2CMC)
1:10(0.1CMC), 1:10(1CMC)
1:10(0.1CMC), 1:10(2CMC)
1:10(1CMC), 1:10(2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for Cell viability
Effect: Column 1
Significance Level: 5 %
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Table  4-8 Pluronic F68 Anova statistics 
TE=Transfection Efficiency 
 
37.256 1.929 <.0001 S
37.511 1.929 <.0001 S
37.600 1.929 <.0001 S
36.367 1.929 <.0001 S
36.689 1.929 <.0001 S
37.467 1.929 <.0001 S
27.611 1.929 <.0001 S
29.322 1.929 <.0001 S
32.378 1.929 <.0001 S
.256 1.929 .6197
.344 1.929 .5046
-.889 1.929 .0948
-.567 1.929 .2769
.211 1.929 .6815
-9.644 1.929 <.0001 S
-7.933 1.929 <.0001 S
-4.878 1.929 <.0001 S
.089 1.929 .8626
-1.144 1.929 .0353
-.822 1.929 .1205
-.044 1.929 .9310
-9.900 1.929 <.0001 S
-8.189 1.929 <.0001 S
-5.133 1.929 <.0001 S
-1.233 1.929 .0245
-.911 1.929 .0874
-.133 1.929 .7952
-9.989 1.929 <.0001 S
-8.278 1.929 <.0001 S
-5.222 1.929 <.0001 S
.322 1.929 .5322
1.100 1.929 .0422
-8.756 1.929 <.0001 S
-7.044 1.929 <.0001 S
-3.989 1.929 <.0001 S
.778 1.929 .1406
-9.078 1.929 <.0001 S
-7.367 1.929 <.0001 S
-4.311 1.929 <.0001 S
-9.856 1.929 <.0001 S
-8.144 1.929 <.0001 S
-5.089 1.929 <.0001 S
1.711 1.929 .0030
4.767 1.929 <.0001 S
3.056 1.929 <.0001 S
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2 (0.1CM...
Lipofectamine, 1:2 (1CMC)
Lipofectamine, 1:2 (2CMC)
Lipofectamine, 1:5 (0.1CM...
Lipofectamine, 1:5 (1CMC)
Lipofectamine, 1:5 (2CMC)
Lipofectamine, 1:10 (0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2 (0.1CMC), 1:2 (1CMC)
1:2 (0.1CMC), 1:2 (2CMC)
1:2 (0.1CMC), 1:5 (0.1CMC)
1:2 (0.1CMC), 1:5 (1CMC)
1:2 (0.1CMC), 1:5 (2CMC)
1:2 (0.1CMC), 1:10 (0.1C...
1:2 (0.1CMC), 1:10 (1CMC)
1:2 (0.1CMC), 1:10 (2CMC)
1:2 (1CMC), 1:2 (2CMC)
1:2 (1CMC), 1:5 (0.1CMC)
1:2 (1CMC), 1:5 (1CMC)
1:2 (1CMC), 1:5 (2CMC)
1:2 (1CMC), 1:10 (0.1CMC)
1:2 (1CMC), 1:10 (1CMC)
1:2 (1CMC), 1:10 (2CMC)
1:2 (2CMC), 1:5 (0.1CMC)
1:2 (2CMC), 1:5 (1CMC)
1:2 (2CMC), 1:5 (2CMC)
1:2 (2CMC), 1:10 (0.1CMC)
1:2 (2CMC), 1:10 (1CMC)
1:2 (2CMC), 1:10 (2CMC)
1:5 (0.1CMC), 1:5 (1CMC)
1:5 (0.1CMC), 1:5 (2CMC)
1:5 (0.1CMC), 1:10 (0.1C...
1:5 (0.1CMC), 1:10 (1CMC)
1:5 (0.1CMC), 1:10 (2CMC)
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for TE
Effect: Column 1
Significance Level: 5 %
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-39.256 2.673 <.0001 S
-31.467 2.673 <.0001 S
-1.589 2.673 .0350
-10.344 2.673 <.0001 S
-19.922 2.673 <.0001 S
-31.567 2.673 <.0001 S
-19.322 2.673 <.0001 S
-24.122 2.673 <.0001 S
-25.800 2.673 <.0001 S
7.789 2.673 <.0001 S
37.667 2.673 <.0001 S
28.911 2.673 <.0001 S
19.333 2.673 <.0001 S
7.689 2.673 <.0001 S
19.933 2.673 <.0001 S
15.133 2.673 <.0001 S
13.456 2.673 <.0001 S
29.878 2.673 <.0001 S
21.122 2.673 <.0001 S
11.544 2.673 <.0001 S
-.100 2.673 .8882
12.144 2.673 <.0001 S
7.344 2.673 <.0001 S
5.667 2.673 <.0001 S
-8.756 2.673 <.0001 S
-18.333 2.673 <.0001 S
-29.978 2.673 <.0001 S
-17.733 2.673 <.0001 S
-22.533 2.673 <.0001 S
-24.211 2.673 <.0001 S
-9.578 2.673 <.0001 S
-21.222 2.673 <.0001 S
-8.978 2.673 <.0001 S
-13.778 2.673 <.0001 S
-15.456 2.673 <.0001 S
-11.644 2.673 <.0001 S
.600 2.673 .4032
-4.200 2.673 <.0001 S
-5.878 2.673 <.0001 S
12.244 2.673 <.0001 S
7.444 2.673 <.0001 S
5.767 2.673 <.0001 S
-4.800 2.673 <.0001 S
-6.478 2.673 <.0001 S
-1.678 2.673 .0269
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2 (0.1CM...
Lipofectamine, 1:2 (1CMC)
Lipofectamine, 1:2 (2CMC)
Lipofectamine, 1:5 (0.1CM...
Lipofectamine, 1:5 (1CMC)
Lipofectamine, 1:5 (2CMC)
Lipofectamine, 1:10 (0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2 (0.1CMC), 1:2 (1CMC)
1:2 (0.1CMC), 1:2 (2CMC)
1:2 (0.1CMC), 1:5 (0.1CMC)
1:2 (0.1CMC), 1:5 (1CMC)
1:2 (0.1CMC), 1:5 (2CMC)
1:2 (0.1CMC), 1:10 (0.1C...
1:2 (0.1CMC), 1:10 (1CMC)
1:2 (0.1CMC), 1:10 (2CMC)
1:2 (1CMC), 1:2 (2CMC)
1:2 (1CMC), 1:5 (0.1CMC)
1:2 (1CMC), 1:5 (1CMC)
1:2 (1CMC), 1:5 (2CMC)
1:2 (1CMC), 1:10 (0.1CMC)
1:2 (1CMC), 1:10 (1CMC)
1:2 (1CMC), 1:10 (2CMC)
1:2 (2CMC), 1:5 (0.1CMC)
1:2 (2CMC), 1:5 (1CMC)
1:2 (2CMC), 1:5 (2CMC)
1:2 (2CMC), 1:10 (0.1CMC)
1:2 (2CMC), 1:10 (1CMC)
1:2 (2CMC), 1:10 (2CMC)
1:5 (0.1CMC), 1:5 (1CMC)
1:5 (0.1CMC), 1:5 (2CMC)
1:5 (0.1CMC), 1:10 (0.1C...
1:5 (0.1CMC), 1:10 (1CMC)
1:5 (0.1CMC), 1:10 (2CMC)
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for Cell viability
Effect: Column 1
Significance Level: 5 %
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Table  4-9 Pluronic F87 Anova statistics 
TE=Transfection Effeciency 
 
 
-4.633 2.188 <.0001 S
3.900 2.188 <.0001 S
-2.678 2.188 .0002 S
-3.933 2.188 <.0001 S
-7.711 2.188 <.0001 S
3.622 2.188 <.0001 S
2.133 2.188 .0014
3.533 2.188 <.0001 S
-26.078 2.188 <.0001 S
8.533 2.188 <.0001 S
1.956 2.188 .0028
.700 2.188 .2378
-3.078 2.188 <.0001 S
8.256 2.188 <.0001 S
6.767 2.188 <.0001 S
8.167 2.188 <.0001 S
-21.444 2.188 <.0001 S
-6.578 2.188 <.0001 S
-7.833 2.188 <.0001 S
-11.611 2.188 <.0001 S
-.278 2.188 .6344
-1.767 2.188 .0060
-.367 2.188 .5311
-29.978 2.188 <.0001 S
-1.256 2.188 .0411
-5.033 2.188 <.0001 S
6.300 2.188 <.0001 S
4.811 2.188 <.0001 S
6.211 2.188 <.0001 S
-23.400 2.188 <.0001 S
-3.778 2.188 <.0001 S
7.556 2.188 <.0001 S
6.067 2.188 <.0001 S
7.467 2.188 <.0001 S
-22.144 2.188 <.0001 S
11.333 2.188 <.0001 S
9.844 2.188 <.0001 S
11.244 2.188 <.0001 S
-18.367 2.188 <.0001 S
-1.489 2.188 .0176
-.089 2.188 .8787
-29.700 2.188 <.0001 S
1.400 2.188 .0244
-28.211 2.188 <.0001 S
-29.611 2.188 <.0001 S
Mean Diff. Crit. Diff P-Value
1:2 (0.1 CMC), 1:2 (1 CMC)
1:2 (0.1 CMC), 1:2 (2 CMC)
1:2 (0.1 CMC), 1:5 (0.1 C...
1:2 (0.1 CMC), 1:5 (1CMC)
1:2 (0.1 CMC), 1:5 (2CMC)
1:2 (0.1 CMC), 1:10 (0.1C...
1:2 (0.1 CMC), 1:10 (1CMC)
1:2 (0.1 CMC), 1:10 (2CMC)
1:2 (0.1 CMC), Lipofectam...
1:2 (1 CMC), 1:2 (2 CMC)
1:2 (1 CMC), 1:5 (0.1 CMC)
1:2 (1 CMC), 1:5 (1CMC)
1:2 (1 CMC), 1:5 (2CMC)
1:2 (1 CMC), 1:10 (0.1CMC)
1:2 (1 CMC), 1:10 (1CMC)
1:2 (1 CMC), 1:10 (2CMC)
1:2 (1 CMC), Lipofectamine
1:2 (2 CMC), 1:5 (0.1 CMC)
1:2 (2 CMC), 1:5 (1CMC)
1:2 (2 CMC), 1:5 (2CMC)
1:2 (2 CMC), 1:10 (0.1CMC)
1:2 (2 CMC), 1:10 (1CMC)
1:2 (2 CMC), 1:10 (2CMC)
1:2 (2 CMC), Lipofectamine
1:5 (0.1 CMC), 1:5 (1CMC)
1:5 (0.1 CMC), 1:5 (2CMC)
1:5 (0.1 CMC), 1:10 (0.1C...
1:5 (0.1 CMC), 1:10 (1CMC)
1:5 (0.1 CMC), 1:10 (2CMC)
1:5 (0.1 CMC), Lipofectam...
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (1CMC), Lipofectamine
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:5 (2CMC), Lipofectamine
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (0.1CMC), Lipofecta...
1:10 (1CMC), 1:10 (2CMC)
1:10 (1CMC), Lipofectamine
1:10 (2CMC), Lipofectamine
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for TE
Effect: Column 1
Significance Level: 5 %
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1.889 3.312 .0423
10.056 3.312 <.0001 S
8.256 3.312 <.0001 S
14.578 3.312 <.0001 S
19.411 3.312 <.0001 S
12.300 3.312 <.0001 S
16.778 3.312 <.0001 S
21.244 3.312 <.0001 S
32.922 3.312 <.0001 S
8.167 3.312 <.0001 S
6.367 3.312 <.0001 S
12.689 3.312 <.0001 S
17.522 3.312 <.0001 S
10.411 3.312 <.0001 S
14.889 3.312 <.0001 S
19.356 3.312 <.0001 S
31.033 3.312 <.0001 S
-1.800 3.312 .0519
4.522 3.312 <.0001 S
9.356 3.312 <.0001 S
2.244 3.312 .0180
6.722 3.312 <.0001 S
11.189 3.312 <.0001 S
22.867 3.312 <.0001 S
6.322 3.312 <.0001 S
11.156 3.312 <.0001 S
4.044 3.312 .0002 S
8.522 3.312 <.0001 S
12.989 3.312 <.0001 S
24.667 3.312 <.0001 S
4.833 3.312 <.0001 S
-2.278 3.312 .0165
2.200 3.312 .0201
6.667 3.312 <.0001 S
18.344 3.312 <.0001 S
-7.111 3.312 <.0001 S
-2.633 3.312 .0067
1.833 3.312 .0481
13.511 3.312 <.0001 S
4.478 3.312 <.0001 S
8.944 3.312 <.0001 S
20.622 3.312 <.0001 S
4.467 3.312 <.0001 S
16.144 3.312 <.0001 S
11.678 3.312 <.0001 S
Mean Diff. Crit. Diff P-Value
1:2 (0.1 CMC), 1:2 (1 CMC)
1:2 (0.1 CMC), 1:2 (2 CMC)
1:2 (0.1 CMC), 1:5 (0.1 C...
1:2 (0.1 CMC), 1:5 (1CMC)
1:2 (0.1 CMC), 1:5 (2CMC)
1:2 (0.1 CMC), 1:10 (0.1C...
1:2 (0.1 CMC), 1:10 (1CMC)
1:2 (0.1 CMC), 1:10 (2CMC)
1:2 (0.1 CMC), Lipofectam...
1:2 (1 CMC), 1:2 (2 CMC)
1:2 (1 CMC), 1:5 (0.1 CMC)
1:2 (1 CMC), 1:5 (1CMC)
1:2 (1 CMC), 1:5 (2CMC)
1:2 (1 CMC), 1:10 (0.1CMC)
1:2 (1 CMC), 1:10 (1CMC)
1:2 (1 CMC), 1:10 (2CMC)
1:2 (1 CMC), Lipofectamine
1:2 (2 CMC), 1:5 (0.1 CMC)
1:2 (2 CMC), 1:5 (1CMC)
1:2 (2 CMC), 1:5 (2CMC)
1:2 (2 CMC), 1:10 (0.1CMC)
1:2 (2 CMC), 1:10 (1CMC)
1:2 (2 CMC), 1:10 (2CMC)
1:2 (2 CMC), Lipofectamine
1:5 (0.1 CMC), 1:5 (1CMC)
1:5 (0.1 CMC), 1:5 (2CMC)
1:5 (0.1 CMC), 1:10 (0.1C...
1:5 (0.1 CMC), 1:10 (1CMC)
1:5 (0.1 CMC), 1:10 (2CMC)
1:5 (0.1 CMC), Lipofectam...
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (1CMC), Lipofectamine
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:5 (2CMC), Lipofectamine
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (0.1CMC), Lipofecta...
1:10 (1CMC), 1:10 (2CMC)
1:10 (1CMC), Lipofectamine
1:10 (2CMC), Lipofectamine
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for Cell viability
Effect: Column 1
Significance Level: 5 %
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Table  4-10 Pluronic F108 Anova statistics 
TE=Transfection Effeciency 
 
25.967 1.325 <.0001 S
26.289 1.325 <.0001 S
25.533 1.325 <.0001 S
21.100 1.325 <.0001 S
13.567 1.325 <.0001 S
13.622 1.325 <.0001 S
24.267 1.325 <.0001 S
24.333 1.325 <.0001 S
21.922 1.325 <.0001 S
.322 1.325 .3660
-.433 1.325 .2279
-4.867 1.325 <.0001 S
-12.400 1.325 <.0001 S
-12.344 1.325 <.0001 S
-1.700 1.325 <.0001 S
-1.633 1.325 .0001 S
-4.044 1.325 <.0001 S
-.756 1.325 .0423
-5.189 1.325 <.0001 S
-12.722 1.325 <.0001 S
-12.667 1.325 <.0001 S
-2.022 1.325 <.0001 S
-1.956 1.325 <.0001 S
-4.367 1.325 <.0001 S
-4.433 1.325 <.0001 S
-11.967 1.325 <.0001 S
-11.911 1.325 <.0001 S
-1.267 1.325 .0016
-1.200 1.325 .0026
-3.611 1.325 <.0001 S
-7.533 1.325 <.0001 S
-7.478 1.325 <.0001 S
3.167 1.325 <.0001 S
3.233 1.325 <.0001 S
.822 1.325 .0285
.056 1.325 .8749
10.700 1.325 <.0001 S
10.767 1.325 <.0001 S
8.356 1.325 <.0001 S
10.644 1.325 <.0001 S
10.711 1.325 <.0001 S
8.300 1.325 <.0001 S
.067 1.325 .8502
-2.344 1.325 <.0001 S
-2.411 1.325 <.0001 S
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2 (0.1CM...
Lipofectamine, 1:2 (1CMC)
Lipofectamine, 1:2 (2CMC)
Lipofectamine, 1:5 (0.1CM...
Lipofectamine, 1:5 (1CMC)
Lipofectamine, 1:5 (2CMC)
Lipofectamine, 1:10 (0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2 (0.1CMC), 1:2 (1CMC)
1:2 (0.1CMC), 1:2 (2CMC)
1:2 (0.1CMC), 1:5 (0.1CMC)
1:2 (0.1CMC), 1:5 (1CMC)
1:2 (0.1CMC), 1:5 (2CMC)
1:2 (0.1CMC), 1:10 (0.1C...
1:2 (0.1CMC), 1:10 (1CMC)
1:2 (0.1CMC), 1:10 (2CMC)
1:2 (1CMC), 1:2 (2CMC)
1:2 (1CMC), 1:5 (0.1CMC)
1:2 (1CMC), 1:5 (1CMC)
1:2 (1CMC), 1:5 (2CMC)
1:2 (1CMC), 1:10 (0.1CMC)
1:2 (1CMC), 1:10 (1CMC)
1:2 (1CMC), 1:10 (2CMC)
1:2 (2CMC), 1:5 (0.1CMC)
1:2 (2CMC), 1:5 (1CMC)
1:2 (2CMC), 1:5 (2CMC)
1:2 (2CMC), 1:10 (0.1CMC)
1:2 (2CMC), 1:10 (1CMC)
1:2 (2CMC), 1:10 (2CMC)
1:5 (0.1CMC), 1:5 (1CMC)
1:5 (0.1CMC), 1:5 (2CMC)
1:5 (0.1CMC), 1:10 (0.1C...
1:5 (0.1CMC), 1:10 (1CMC)
1:5 (0.1CMC), 1:10 (2CMC)
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for TE
Effect: Column 1
Significance Level: 5 %
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-24.556 2.286 <.0001 S
-30.967 2.286 <.0001 S
-10.367 2.286 <.0001 S
-19.811 2.286 <.0001 S
-7.433 2.286 <.0001 S
-10.589 2.286 <.0001 S
-3.733 2.286 <.0001 S
-6.256 2.286 <.0001 S
-3.967 2.286 <.0001 S
-6.411 2.286 <.0001 S
14.189 2.286 <.0001 S
4.744 2.286 <.0001 S
17.122 2.286 <.0001 S
13.967 2.286 <.0001 S
20.822 2.286 <.0001 S
18.300 2.286 <.0001 S
20.589 2.286 <.0001 S
20.600 2.286 <.0001 S
11.156 2.286 <.0001 S
23.533 2.286 <.0001 S
20.378 2.286 <.0001 S
27.233 2.286 <.0001 S
24.711 2.286 <.0001 S
27.000 2.286 <.0001 S
-9.444 2.286 <.0001 S
2.933 2.286 <.0001 S
-.222 2.286 .7154
6.633 2.286 <.0001 S
4.111 2.286 <.0001 S
6.400 2.286 <.0001 S
12.378 2.286 <.0001 S
9.222 2.286 <.0001 S
16.078 2.286 <.0001 S
13.556 2.286 <.0001 S
15.844 2.286 <.0001 S
-3.156 2.286 <.0001 S
3.700 2.286 <.0001 S
1.178 2.286 .0641
3.467 2.286 <.0001 S
6.856 2.286 <.0001 S
4.333 2.286 <.0001 S
6.622 2.286 <.0001 S
-2.522 2.286 .0004 S
-.233 2.286 .7019
2.289 2.286 .0011 S
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2 (0.1CM...
Lipofectamine, 1:2 (1CMC)
Lipofectamine, 1:2 (2CMC)
Lipofectamine, 1:5 (0.1CM...
Lipofectamine, 1:5 (1CMC)
Lipofectamine, 1:5 (2CMC)
Lipofectamine, 1:10 (0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2 (0.1CMC), 1:2 (1CMC)
1:2 (0.1CMC), 1:2 (2CMC)
1:2 (0.1CMC), 1:5 (0.1CMC)
1:2 (0.1CMC), 1:5 (1CMC)
1:2 (0.1CMC), 1:5 (2CMC)
1:2 (0.1CMC), 1:10 (0.1C...
1:2 (0.1CMC), 1:10 (1CMC)
1:2 (0.1CMC), 1:10 (2CMC)
1:2 (1CMC), 1:2 (2CMC)
1:2 (1CMC), 1:5 (0.1CMC)
1:2 (1CMC), 1:5 (1CMC)
1:2 (1CMC), 1:5 (2CMC)
1:2 (1CMC), 1:10 (0.1CMC)
1:2 (1CMC), 1:10 (1CMC)
1:2 (1CMC), 1:10 (2CMC)
1:2 (2CMC), 1:5 (0.1CMC)
1:2 (2CMC), 1:5 (1CMC)
1:2 (2CMC), 1:5 (2CMC)
1:2 (2CMC), 1:10 (0.1CMC)
1:2 (2CMC), 1:10 (1CMC)
1:2 (2CMC), 1:10 (2CMC)
1:5 (0.1CMC), 1:5 (1CMC)
1:5 (0.1CMC), 1:5 (2CMC)
1:5 (0.1CMC), 1:10 (0.1C...
1:5 (0.1CMC), 1:10 (1CMC)
1:5 (0.1CMC), 1:10 (2CMC)
1:5 (1CMC), 1:5 (2CMC)
1:5 (1CMC), 1:10 (0.1CMC)
1:5 (1CMC), 1:10 (1CMC)
1:5 (1CMC), 1:10 (2CMC)
1:5 (2CMC), 1:10 (0.1CMC)
1:5 (2CMC), 1:10 (1CMC)
1:5 (2CMC), 1:10 (2CMC)
1:10 (0.1CMC), 1:10 (1CM...
1:10 (0.1CMC), 1:10 (2CM...
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for Cell viability
Effect: Column 1
Significance Level: 5 %
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Table  4-11 Pluronic F127 Anova statistics 
TE=Transfection Effeciency  
 
27.810 1.037 <.0001 S
29.829 1.037 <.0001 S
29.857 1.037 <.0001 S
26.924 1.037 <.0001 S
29.457 1.037 <.0001 S
29.057 1.037 <.0001 S
29.848 1.037 <.0001 S
27.971 1.037 <.0001 S
27.876 1.037 <.0001 S
2.019 1.037 <.0001 S
2.048 1.037 <.0001 S
-.886 1.037 .0040
1.648 1.037 <.0001 S
1.248 1.037 .0002 S
2.038 1.037 <.0001 S
.162 1.037 .5591
.067 1.037 .8092
.029 1.037 .9175
-2.905 1.037 <.0001 S
-.371 1.037 .1880
-.771 1.037 .0103
.019 1.037 .9450
-1.857 1.037 <.0001 S
-1.952 1.037 <.0001 S
-2.933 1.037 <.0001 S
-.400 1.037 .1577
-.800 1.037 .0082
-.010 1.037 .9725
-1.886 1.037 <.0001 S
-1.981 1.037 <.0001 S
2.533 1.037 <.0001 S
2.133 1.037 <.0001 S
2.924 1.037 <.0001 S
1.048 1.037 .0010 S
.952 1.037 .0023
-.400 1.037 .1577
.390 1.037 .1673
-1.486 1.037 <.0001 S
-1.581 1.037 <.0001 S
.790 1.037 .0088
-1.086 1.037 .0007 S
-1.181 1.037 .0003 S
-1.876 1.037 <.0001 S
-1.971 1.037 <.0001 S
-.095 1.037 .7304
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2(0.1CMC)
Lipofectamine, 1:2(1CMC)
Lipofectamine, 1:2(2CMC)
Lipofectamine, 1:5(0.1CMC)
Lipofectamine, 1:5(1CMC)
Lipofectamine, 1:5(2CMC)
Lipofectamine, 1:10(0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2(0.1CMC), 1:2(1CMC)
1:2(0.1CMC), 1:2(2CMC)
1:2(0.1CMC), 1:5(0.1CMC)
1:2(0.1CMC), 1:5(1CMC)
1:2(0.1CMC), 1:5(2CMC)
1:2(0.1CMC), 1:10(0.1CMC)
1:2(0.1CMC), 1:10 (1CMC)
1:2(0.1CMC), 1:10 (2CMC)
1:2(1CMC), 1:2(2CMC)
1:2(1CMC), 1:5(0.1CMC)
1:2(1CMC), 1:5(1CMC)
1:2(1CMC), 1:5(2CMC)
1:2(1CMC), 1:10(0.1CMC)
1:2(1CMC), 1:10 (1CMC)
1:2(1CMC), 1:10 (2CMC)
1:2(2CMC), 1:5(0.1CMC)
1:2(2CMC), 1:5(1CMC)
1:2(2CMC), 1:5(2CMC)
1:2(2CMC), 1:10(0.1CMC)
1:2(2CMC), 1:10 (1CMC)
1:2(2CMC), 1:10 (2CMC)
1:5(0.1CMC), 1:5(1CMC)
1:5(0.1CMC), 1:5(2CMC)
1:5(0.1CMC), 1:10(0.1CMC)
1:5(0.1CMC), 1:10 (1CMC)
1:5(0.1CMC), 1:10 (2CMC)
1:5(1CMC), 1:5(2CMC)
1:5(1CMC), 1:10(0.1CMC)
1:5(1CMC), 1:10 (1CMC)
1:5(1CMC), 1:10 (2CMC)
1:5(2CMC), 1:10(0.1CMC)
1:5(2CMC), 1:10 (1CMC)
1:5(2CMC), 1:10 (2CMC)
1:10(0.1CMC), 1:10 (1CMC)
1:10(0.1CMC), 1:10 (2CMC)
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for TE
Effect: Column 1
Significance Level: 5 %
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-18.105 2.719 <.0001 S
-28.095 2.719 <.0001 S
-5.981 2.719 <.0001 S
-8.495 2.719 <.0001 S
6.086 2.719 <.0001 S
5.152 2.719 <.0001 S
4.105 2.719 <.0001 S
-3.219 2.719 .0002 S
-4.391 2.719 <.0001 S
-9.990 2.719 <.0001 S
12.124 2.719 <.0001 S
9.610 2.719 <.0001 S
24.190 2.719 <.0001 S
23.257 2.719 <.0001 S
22.210 2.719 <.0001 S
14.886 2.719 <.0001 S
13.714 2.719 <.0001 S
22.114 2.719 <.0001 S
19.600 2.719 <.0001 S
34.181 2.719 <.0001 S
33.248 2.719 <.0001 S
32.200 2.719 <.0001 S
24.876 2.719 <.0001 S
23.705 2.719 <.0001 S
-2.514 2.719 .0022
12.067 2.719 <.0001 S
11.133 2.719 <.0001 S
10.086 2.719 <.0001 S
2.762 2.719 .0010 S
1.590 2.719 .0377
14.581 2.719 <.0001 S
13.648 2.719 <.0001 S
12.600 2.719 <.0001 S
5.276 2.719 <.0001 S
4.105 2.719 <.0001 S
-.933 2.719 .2065
-1.981 2.719 .0118
-9.305 2.719 <.0001 S
-10.476 2.719 <.0001 S
-1.048 2.719 .1583
-8.371 2.719 <.0001 S
-9.543 2.719 <.0001 S
-7.324 2.719 <.0001 S
-8.495 2.719 <.0001 S
-1.171 2.719 .1169
Mean Diff. Crit. Diff P-Value
Lipofectamine, 1:2(0.1CMC)
Lipofectamine, 1:2(1CMC)
Lipofectamine, 1:2(2CMC)
Lipofectamine, 1:5(0.1CMC)
Lipofectamine, 1:5(1CMC)
Lipofectamine, 1:5(2CMC)
Lipofectamine, 1:10(0.1C...
Lipofectamine, 1:10 (1CMC)
Lipofectamine, 1:10 (2CMC)
1:2(0.1CMC), 1:2(1CMC)
1:2(0.1CMC), 1:2(2CMC)
1:2(0.1CMC), 1:5(0.1CMC)
1:2(0.1CMC), 1:5(1CMC)
1:2(0.1CMC), 1:5(2CMC)
1:2(0.1CMC), 1:10(0.1CMC)
1:2(0.1CMC), 1:10 (1CMC)
1:2(0.1CMC), 1:10 (2CMC)
1:2(1CMC), 1:2(2CMC)
1:2(1CMC), 1:5(0.1CMC)
1:2(1CMC), 1:5(1CMC)
1:2(1CMC), 1:5(2CMC)
1:2(1CMC), 1:10(0.1CMC)
1:2(1CMC), 1:10 (1CMC)
1:2(1CMC), 1:10 (2CMC)
1:2(2CMC), 1:5(0.1CMC)
1:2(2CMC), 1:5(1CMC)
1:2(2CMC), 1:5(2CMC)
1:2(2CMC), 1:10(0.1CMC)
1:2(2CMC), 1:10 (1CMC)
1:2(2CMC), 1:10 (2CMC)
1:5(0.1CMC), 1:5(1CMC)
1:5(0.1CMC), 1:5(2CMC)
1:5(0.1CMC), 1:10(0.1CMC)
1:5(0.1CMC), 1:10 (1CMC)
1:5(0.1CMC), 1:10 (2CMC)
1:5(1CMC), 1:5(2CMC)
1:5(1CMC), 1:10(0.1CMC)
1:5(1CMC), 1:10 (1CMC)
1:5(1CMC), 1:10 (2CMC)
1:5(2CMC), 1:10(0.1CMC)
1:5(2CMC), 1:10 (1CMC)
1:5(2CMC), 1:10 (2CMC)
1:10(0.1CMC), 1:10 (1CMC)
1:10(0.1CMC), 1:10 (2CMC)
1:10 (1CMC), 1:10 (2CMC)
Comparisons in this table are not signif icant unless the
corresponding p-value is less than .0011.
Bonferroni/Dunn for Column 1.3
Effect: Column 1
Significance Level: 5 %
